Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

17. Referanser

Aberle, D. R., Adams, A. M., Berg, C. D., Black, W. C., Clapp, J. D., Fagerstrom, R. M., . . . National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5), 395-409. https://doi.org/10.1056/NEJMoa1102873

Aberle, D. R., DeMello, S., Berg, C. D., Black, W. C., Brewer, B., Church, T. R., . . . National Lung Screening Trial Research Team. (2013). Results of the two incidence screenings in the National Lung Screening Trial. New England Journal of Medicine, 369(10), 920-931. https://doi.org/10.1056/NEJMoa1208962

Adabag, A. S., Wassif, H. S., Rice, K., Mithani, S., Johnson, D., Bonawitz-Conlin, J., . . . Kelly, R. F. (2010). Preoperative pulmonary function and mortality after cardiac surgery. American Heart Journal, 159(4), 691-697. https://doi.org/10.1016/j.ahj.2009.12.039

Adams, R. F., Gray, W., Davies, R. J., & Gleeson, F. V. (2001). Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest, 120(6), 1798-1802.

Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., . . . Caravaggio Investigators. (2020). Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. New England Journal of Medicine, 382(17), 1599-1607. https://doi.org/10.1056/NEJMoa1915103

Aguilar, E., Gainor, J., Kravets, S., Khosrowjerdi, S., Lydon, C., Adeni, A., . . . Awad, M. (2018). Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 0-89% vs 90-100%. Journal of Thoracic Oncology, 13(10), S367-S368.

Al-Sahaf, M., & Lim, E. (2015). The association between surgical volume, survival and quality of care. Journal of Thoracic Disease, 7(Suppl 2), S152-155. https://doi.org/10.3978/j.issn.2072-1439.2015.04.08

Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., . . . Cox, J. D. (2009). Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet, 374(9687), 379-386. https://doi.org/10.1016/S0140-6736(09)60737-6

Alberts, W. M., & American College of Chest Physicians. (2007). Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest, 132(3 Suppl), 1S-19S. https://doi.org/10.1378/chest.07-1860

Ambrosini, V., Nicolini, S., Caroli, P., Nanni, C., Massaro, A., Marzola, M. C., . . . Fanti, S. (2012). PET/CT imaging in different types of lung cancer: an overview. European Journal of Radiology, 81(5), 988-1001. https://doi.org/10.1016/j.ejrad.2011.03.020

Anderson, G., & Takahama, Y. (2012). Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends in Immunology, 33(6), 256-263. https://doi.org/10.1016/j.it.2012.03.005

Anderson, K. L., Mulvihill, M. S., Speicher, P. J., Yerokun, B. A., Gulack, B. C., Nussbaum, D. P., . . . Hartwig, M. G. (2017). Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Annals of Thoracic Surgery, 104(4), 1221-1230. https://doi.org/10.1016/j.athoracsur.2017.05.011

Ando, K., Akimoto, K., Sato, H., Manabe, R., Kishino, Y., Homma, T., . . . Sagara, H. (2020). Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. Cancers, 12(4). https://doi.org/10.3390/cancers12040942

Annema, J. T., van Meerbeeck, J. P., Rintoul, R. C., Dooms, C., Deschepper, E., Dekkers, O. M., . . . Tournoy, K. G. (2010). Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA, 304(20), 2245-2252. https://doi.org/10.1001/jama.2010.1705

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., . . . PACIFIC Investigators. (2018). Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 379(24), 2342-2350. https://doi.org/10.1056/NEJMoa1809697

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., . . . PACIFIC Investigators. (2017). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 377(20), 1919-1929. https://doi.org/10.1056/NEJMoa1709937

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., . . . Hellmann, M. D. (2018). Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36(28), 2872-2878. https://doi.org/10.1200/JCO.2018.79.0006

Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., . . . Preiser, J. C. (2017). ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition, 36(1), 11-48. https://doi.org/10.1016/j.clnu.2016.07.015

Arrieta, O., Cardona, A. F., Lara-Mejía, L., Heredia, D., Barrón, F., Zatarain-Barrón, Z. L., . . . Rosell, R. (2020). Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. Critical Reviews in Oncology/Hematology, 153, 103033. https://doi.org/10.1016/j.critrevonc.2020.103033

Asamura, H., Chansky, K., Crowley, J., Goldstraw, P., Rusch, V. W., Vansteenkiste, J. F., . . . International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, A. v. B. M., and Participating Institutions,. (2015). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 10(12), 1675-1684. https://doi.org/10.1097/JTO.0000000000000678

Ashraf, H., Dirksen, A., Loft, A., Bertelsen, A. K., Bach, K. S., Hansen, H., . . . Mortensen, J. (2011). Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax, 66(4), 315-319. https://doi.org/10.1136/thx.2010.136747

Auperin, A., Arriagada, R., Pignon, J. P., Le Pechoux, C., Gregor, A., Stephens, R. J., . . . Aisner, J. (1999). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. New England Journal of Medicine, 341(7), 476-484.

Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., . . . Pignon, J. P. (2010). Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Journal of Clinical Oncology, 28(13), 2181-2190. https://doi.org/10.1200/JCO.2009.26.2543

Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., . . . Sholl, L. M. (2016). MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2015.63.4600

Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., . . . Giaccone, G. (2009). American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 27(36), 6251-6266.

Baize, N., Monnet, I., Greillier, L., Geier, M., Lena, H., Janicot, H., . . . Groupe Français de Pneumo-Cancérologie 01–13 investigators. (2020). Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, 21(9), 1224-1233. https://doi.org/10.1016/S1470-2045(20)30461-7

Bankier, A. A., MacMahon, H., Goo, J. M., Rubin, G. D., Schaefer-Prokop, C. M., & Naidich, D. P. (2017). Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. Radiology, 285(2), 584-600. https://doi.org/10.1148/radiol.2017162894

Barlesi, F., Vansteenkiste, J., Spigel, D., Ishii, H., Garassino, M., de Marinis, F., . . . Park, K. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncology. https://doi.org/10.1016/S1470-2045(18)30673-9

Bastarrika, G., García-Velloso, M. J., Lozano, M. D., Montes, U., Torre, W., Spiteri, N., . . . Zulueta, J. J. (2005). Early lung cancer detection using spiral computed tomography and positron emission tomography. American Journal of Respiratory and Critical Care Medicine, 171(12), 1378-1383. https://doi.org/10.1164/rccm.200411-1479OC

Baudin, E., Caplin, M., Garcia-Carbonero, R., Fazio, N., Ferolla, P., Filosso, P. L., . . . ESMO Guidelines Committee. (2021). Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(4), 439-451. https://doi.org/10.1016/j.annonc.2021.01.003

Baumann, P., Nyman, J., Hoyer, M., Gagliardi, G., Lax, I., Wennberg, B., . . . Lewensohn, R. (2008). Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiotherapy and Oncology, 88(3), 359-367. https://doi.org/10.1016/j.radonc.2008.07.019

Baumann, P., Nyman, J., Hoyer, M., Wennberg, B., Gagliardi, G., Lax, I., . . . Lewensohn, R. (2009). Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. Journal of Clinical Oncology, 27(20), 3290-3296.

Benna, M., Guy, J. B., Bosacki, C., Jmour, O., Ben Mrad, M., Ogorodniitchouk, O., . . . Vallard, A. (2020). Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box? British Journal of Radiology, 93(1109), 20190147. https://doi.org/10.1259/bjr.20190147

Berardi, R., De Lisa, M., Pagliaretta, S., Onofri, A., Morgese, F., Savini, A., . . . Cascinu, S. (2014). Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treatment Reviews, 40(4), 495-506. https://doi.org/10.1016/j.ctrv.2013.11.003

Berry, M. F., D'Amico, T. A., Onaitis, M. W., & Kelsey, C. R. (2014). Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. Annals of Thoracic Surgery, 98(1), 197-202. https://doi.org/10.1016/j.athoracsur.2014.03.018

Bhattacharya, S., Bairagya, T. D., Das, A., Mandal, A., & Das, S. K. (2012). Closed pleural biopsy is still useful in the evaluation of malignant pleural effusion. Journal of laboratory physicians, 4(1), 35-38. https://doi.org/10.4103/0974-2727.98669

Bi, N., & Wang, L. (2015). Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy. Seminars in Radiation Oncology, 25(2), 122-132. https://doi.org/10.1016/j.semradonc.2014.11.003

Bilski, M., Mertowska, P., Mertowski, S., Sawicki, M., Hymos, A., Niedźwiedzka-Rystwej, P., & Grywalska, E. (2021). The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung. Cancers, 14(1). https://doi.org/10.3390/cancers14010177

Bischof, M., Debus, J., Herfarth, K., Muley, T., Kappes, J., Storz, K., & Hoffmann, H. (2007). Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. Strahlentherapie und Onkologie, 183(12), 679-684.

Bissett, D., Macbeth, F. R., & Cram, I. (1991). The role of palliative radiotherapy in malignant mesothelioma. Clinical Oncology (Royal College of Radiologists), 3(6), 315-317.

Bolliger, C. T., Sutedja, T. G., Strausz, J., & Freitag, L. (2006). Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. European Respiratory Journal, 27(6), 1258-1271.

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., . . . Brahmer, J. R. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(17), 1627-1639. https://doi.org/10.1056/NEJMoa1507643

Bossé, Y., & Amos, C. I. (2018). A Decade of GWAS Results in Lung Cancer. Cancer Epidemiology, Biomarkers and Prevention, 27(4), 363-379. https://doi.org/10.1158/1055-9965.EPI-16-0794

Boyar Cetinkaya, R., Aagnes, B., Thiis-Evensen, E., Tretli, S., Bergestuen, D. S., & Hansen, S. (2017). Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology, 104(1), 1-10. https://doi.org/10.1159/000442207

Bradbury, P., Sivajohanathan, D., Chan, A., Kulkarni, S., Ung, Y., & Ellis, P. M. (2016). Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2016.07.002

Bradley, J., & Movsas, B. (2004). Radiation esophagitis: Predictive factors and preventive strategies. Seminars in Radiation Oncology, 14(4), 280-286. https://doi.org/10.1016/j.semradonc.2004.06.003

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E., Poddubskaya, E., . . . Spigel, D. R. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(2), 123-135. https://doi.org/10.1056/NEJMoa1504627

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., . . . Ernstoff, M. S. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for immunotherapy of cancer, 9(6). https://doi.org/10.1136/jitc-2021-002435

Brcic, L., & Kern, I. (2020). Clinical significance of histologic subtyping of malignant pleural mesothelioma. Translational lung cancer research, 9(3), 924-933. https://doi.org/10.21037/tlcr.2020.03.38

Brokx, H. A. P., Risse, E. K., Paul, M. A., Grunberg, K., Golding, R. P., Kunst, P. W. A., . . . Sutedja, T. G. (2007). Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. Journal of Thoracic and Cardiovascular Surgery, 133(4), 973-978.

Brown, D. J. (2006). Palliation of breathlessness. Clinical medicine, 6(2), 133-136. https://doi.org/10.7861/clinmedicine.6-2-133

Brown, P. D., Ballman, K. V., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Whitton, A. C., . . . Roberge, D. (2017). Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, 18(8), 1049-1060. https://doi.org/10.1016/S1470-2045(17)30441-2

Brunelli, A., Belardinelli, R., Pompili, C., Xiumé, F., Refai, M., Salati, M., & Sabbatini, A. (2012). Minute ventilation-to-carbon dioxide output (VE/VCO2) slope is the strongest predictor of respiratory complications and death after pulmonary resection. Annals of Thoracic Surgery, 93(6), 1802-1806. https://doi.org/10.1016/j.athoracsur.2012.03.022

Brunelli, A., Charloux, A., Bolliger, C. T., Rocco, G., Sculier, J. P., Varela, G., . . . European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. (2009). ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). European Respiratory Journal, 34(1), 17-41. https://doi.org/10.1183/09031936.00184308

Brunelli, A., Pompili, C., & Salati, M. (2010). Low-technology exercise test in the preoperative evaluation of lung resection candidates. Monaldi Archives for Chest Disease. Archivio Monaldi per Le Malattie Del Torace, 73(2), 72-78.

Brustugun, O. T., Grønberg, B. H., Fjellbirkeland, L., Helbekkmo, N., Aanerud, M., Grimsrud, T. K., . . . Solberg, S. K. (2018). Substantial nation-wide improvement in lung cancer relative survival in  Norway from 2000 to 2016   Lung Cancer, 122, 138-145.

Brustugun, O. T., Helland, Å., Fjellbirkeland, L., Kleinberg, L., Ariansen, S., Jebsen, P., . . . Helgeland, L. (2012). Mutasjonstesting ved ikke-småcellet lungekreft. Tidsskrift for den Norske Legeforening, 132(8), 952-955.

Brustugun, O. T., Møller, B., & Helland, A. (2014). Years of life lost as a measure of cancer burden on a national level. British Journal of Cancer, 111(5), 1014-1020. https://doi.org/10.1038/bjc.2014.364

Brustugun, O. T., Nilssen, Y., & Eide, I. J. Z. (2021). Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study. Acta Oncologica, 60(10), 1250-1256. https://doi.org/10.1080/0284186X.2021.1955971

Bugge, A. S., Lund, M. B., Valberg, M., Brustugun, O. T., Solberg, S., & Kongerud, J. (2018). Cause-specific death after surgical resection for early-stage non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 53(1), 221-227. https://doi.org/10.1093/ejcts/ezx274

Bunn, P. A., Crowley, J., Kelly, K., Hazuka, M. B., Beasley, K., Upchurch, C., . . . Gandara, D. R. (1995). Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. Journal of Clinical Oncology, 13(7), 1632-1641.

Bunyaviroch, T., & Coleman, R. E. (2006). PET evaluation of lung cancer. Journal of Nuclear Medicine, 47(3), 451-469.

Butts, C. A., Ding, K., Seymour, L., Twumasi-Ankrah, P., Graham, B., Gandara, D., . . . Shepherd, F. A. (2010). Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. Journal of Clinical Oncology, 28(1), 29-34. https://doi.org/10.1200/JCO.2009.24.0333

Bydder, S., Phillips, M., Joseph, D. J., Cameron, F., Spry, N. A., DeMelker, Y., & Musk, A. W. (2004). A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. British Journal of Cancer, 91(1), 9-10.

Bydder, S., Spry, N. A., Christie, D. R. H., Roos, D., Burmeister, B. H., Krawitz, H., . . . Berry, M. (2003). A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australasian Radiology, 47(3), 284-288. https://doi.org/doi:10.1046/j.1440-1673.2003.01177.x

Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., . . . Zalcman, G. (2021). First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, 397(10272), 375-386. https://doi.org/10.1016/S0140-6736(20)32714-8

Callister, M. E., Baldwin, D. R., Akram, A. R., Barnard, S., Cane, P., Draffan, J., . . . British Thoracic Society Standards of Care Committee. (2015). British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, 70 Suppl 2, ii1-ii54. https://doi.org/10.1136/thoraxjnl-2015-207168

Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group. (2013). Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA, 309(8), 814-822. https://doi.org/10.1001/jama.2013.879

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C., Han, J. Y., Lee, J. S., . . . Popat, S. (2018). Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 379(21), 2027-2039. https://doi.org/10.1056/NEJMoa1810171

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C. H., Han, J. Y., Hochmair, M. J., . . . Popat, S. (2020). Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Journal of Clinical Oncology, 38(31), 3592-3603. https://doi.org/10.1200/JCO.20.00505

Camidge, D. R., Pabani, A., Miller, R. M., Rizvi, N. A., & Bazhenova, L. (2019). Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib. Journal of Thoracic Oncology, 14(9), 1547-1555. https://doi.org/10.1016/j.jtho.2019.04.028

Cañizares, M. A., Matilla, J. M., Cueto, A., Algar, J., Muguruza, I., Moreno-Mata, N., . . . EMETNE-SEPAR Members. (2014). Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax, 69(7), 648-653. https://doi.org/10.1136/thoraxjnl-2013-204102

Cannon, D. M., Mehta, M. P., Adkison, J. B., Khuntia, D., Traynor, A. M., Tomé, W. A., . . . Cannon, G. M. (2013). Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. Journal of Clinical Oncology, 31(34), 4343-4348. https://doi.org/10.1200/JCO.2013.51.5353

Cao, C. Q., Yan, T. D., Bannon, P. G., & McCaughan, B. C. (2010). A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Thoracic Oncology, 5(10), 1692-1703. https://doi.org/10.1097/JTO.0b013e3181ed0489

Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., . . . ENETS consensus conference participants. (2015). Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of Oncology. https://doi.org/10.1093/annonc/mdv041

Cardillo, G., Sera, F., Di Martino, M., Graziano, P., Giunti, R., Carbone, L., . . . Martelli, M. (2004). Bronchial carcinoid tumors: nodal status and long-term survival after resection. Annals of Thoracic Surgery, 77(5), 1781-1785. https://doi.org/10.1016/j.athoracsur.2003.10.089

Carter, B. W., Benveniste, M. F., Madan, R., Godoy, M. C., de Groot, P. M., Truong, M. T., . . . Marom, E. M. (2017a). ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses. Radiographics, 37(2), 413-436. https://doi.org/10.1148/rg.2017160095

Carter, B. W., Benveniste, M. F., Madan, R., Godoy, M. C., Groot, P. M., Truong, M. T., . . . Marom, E. M. (2017b). IASLC/ITMIG Staging System and Lymph Node Map for Thymic Epithelial Neoplasms. Radiographics, 37(3), 758-776. https://doi.org/10.1148/rg.2017160096

Cavaliere, S., Venuta, F., Foccoli, P., Toninelli, C., & La Face, B. (1996). Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest, 110(6), 1536-1542.

Chalian, H., Töre, H. G., Horowitz, J. M., Salem, R., Miller, F. H., & Yaghmai, V. (2011). Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics, 31(7), 2093-2105. https://doi.org/10.1148/rg.317115050

Chandrasekar, D., Tribett, E., & Ramchandran, K. (2016). Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer. Current Treatment Options in Oncology, 17(5), 23. https://doi.org/10.1007/s11864-016-0397-1

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., . . . Roth, J. A. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncology. https://doi.org/10.1016/S1470-2045(15)70168-3

Chapel, D. B., Schulte, J. J., Husain, A. N., & Krausz, T. (2020). Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Translational lung cancer research, 9(Suppl 1), S3-S27. https://doi.org/10.21037/tlcr.2019.11.29

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. (1995). BMJ, 311(7010), 899-909.

Chen, G., Huynh, M., Chen, A., Fehrenbacher, L., Gandara, D., & Lau, D. (2008). Chemotherapy for brain metastases in small-cell lung cancer. Clinical Lung Cancer, 9(1), 35-38.

Chen, G., Huynh, M., Fehrenbacher, L., West, H., Lara, P. N., Yavorkovsky, L. L., . . . Lau, D. (2009). Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. Journal of Clinical Oncology, 27(9), 1401-1404. https://doi.org/10.1200/JCO.2008.20.2127

Chen, L., Shen, C., Redmond, K. J., Page, B. R., Kummerlowe, M., Mcnutt, T., . . . Kleinberg, L. (2017). Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 98(4), 939-947. https://doi.org/10.1016/j.ijrobp.2017.02.031

Cheng, S., Evans, W. K., Stys-Norman, D., & Shepherd, F. A. (2007). Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. Journal of Thoracic Oncology, 2(4), 348-354.

Cherny, N. I., Catane, R., Kosmidis, P., & ESMO Taskforce on Supportive and Palliative Care. (2003). ESMO takes a stand on supportive and palliative care. Annals of Oncology, 14(9), 1335-1337. https://doi.org/10.1093/annonc/mdg379

Chiu, C. H., Chern, M. S., Wu, M. H., Hsu, W. H., Wu, Y. C., Huang, M. H., & Chang, S. C. (2003). Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. Journal of Thoracic and Cardiovascular Surgery, 125(6), 1300-1305.

Cho, B. C., Kim, D. W., Bearz, A., Laurie, S. A., McKeage, M., Borra, G., . . . Wrona, A. (2017). ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 12(9), 1357-1367. https://doi.org/10.1016/j.jtho.2017.07.005

Cho, J., Kim, H. S., Ku, B. M., Choi, Y. L., Cristescu, R., Han, J., . . . Ahn, M. J. (2018). Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of Clinical Oncology, JCO2017773184. https://doi.org/10.1200/JCO.2017.77.3184

Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., . . . Ahn, M. J. (2020). Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). Journal of Clinical Oncology, 38(5), 488-495. https://doi.org/10.1200/JCO.19.00931

Christensen, N. L., Jekunen, A., Heinonen, S., Dalton, S. O., & Rasmussen, T. R. (2017). Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison. Acta Oncologica, 56(7), 943-948. https://doi.org/10.1080/0284186X.2017.1315172

Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H., . . . Ott, P. A. (2020). Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology, 15(4), 618-627. https://doi.org/10.1016/j.jtho.2019.12.109

Chung, J. H., Choe, G., Jheon, S., Sung, S. W., Kim, T. J., Lee, K. W., . . . Lee, C. T. (2009). Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. Journal of Thoracic Oncology, 4(12), 1490-1495. https://doi.org/10.1097/JTO.0b013e3181bc9731

Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., . . . Gonzalez, E. E. (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncology, 13(3), 300-308. https://doi.org/10.1016/S1470-2045(11)70385-0

Colt, H. G., Murgu, S. D., Korst, R. J., Slatore, C. G., Unger, M., & Quadrelli, S. (2013). Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e437S-454S. https://doi.org/10.1378/chest.12-2365

Corso, C. D., Rutter, C. E., Wilson, L. D., Kim, A. W., Decker, R. H., & Husain, Z. A. (2015). Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. Journal of Thoracic Oncology, 10(1), 148-155. https://doi.org/10.1097/JTO.0000000000000406

Crona, J., Fanola, I., Lindholm, D. P., Antonodimitrakis, P., Öberg, K., Eriksson, B., & Granberg, D. (2013). Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology, 98(2), 151-155. https://doi.org/10.1159/000354760

Cuffe, S., Booth, C. M., Peng, Y., Darling, G. E., Li, G., Kong, W., . . . Shepherd, F. A. (2012). Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. Journal of Clinical Oncology, 30(15), 1813-1821. https://doi.org/10.1200/JCO.2011.39.3330

D'Urso, V., Doneddu, V., Marchesi, I., Collodoro, A., Pirina, P., Giordano, A., & Bagella, L. (2013). Sputum analysis: non-invasive early lung cancer detection. Journal of Cellular Physiology, 228(5), 945-951. https://doi.org/10.1002/jcp.24263

Dagogo-Jack, I., Moonsamy, P., Gainor, J. F., Lennerz, J. K., Piotrowska, Z., Lin, J. J., . . . Heist, R. S. (2021). A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of Thoracic Oncology, 16(5), 850-859. https://doi.org/10.1016/j.jtho.2021.01.1605

de Alencar, V. T. L., Formiga, M. N., & de Lima, V. C. C. (2020). Inherited lung cancer: a review. Ecancermedicalscience, 14, 1008. https://doi.org/10.3332/ecancer.2020.1008

de Hoop, B., van Ginneken, B., Gietema, H., & Prokop, M. (2012). Pulmonary perifissural nodules on CT scans: rapid growth is not a predictor of malignancy. Radiology, 265(2), 611-616. https://doi.org/10.1148/radiol.12112351

de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., . . . Oudkerk, M. (2020). Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. New England Journal of Medicine, 382(6), 503-513. https://doi.org/10.1056/NEJMoa1911793

de Langen, A. J., Raijmakers, P., Riphagen, I., Paul, M. A., & Hoekstra, O. S. (2006). The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. European Journal of Cardio-Thoracic Surgery, 29(1), 26-29. https://doi.org/10.1016/j.ejcts.2005.10.002

De Leyn, P., Dooms, C., Kuzdzal, J., Lardinois, D., Passlick, B., Rami-Porta, R., . . . Zielinski, M. (2014). Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 45(5), 787-798. https://doi.org/10.1093/ejcts/ezu028

de Perrot, M., Feld, R., Cho, B. C., Bezjak, A., Anraku, M., Burkes, R., . . . Johnston, M. R. (2009). Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. Journal of Clinical Oncology, 27(9), 1413-1418. https://doi.org/10.1200/JCO.2008.17.5604

De Ruysscher, D., Botterweck, A., Dirx, M., Pijls-Johannesma, M., Wanders, R., Hochstenbag, M., . . . Lambin, P. (2009). Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Annals of Oncology, 20(1), 98-102. https://doi.org/10.1093/annonc/mdn559

De Ruysscher, D., Nakagawa, K., & Asamura, H. (2014). Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer. European Respiratory Journal, 44(2), 483-494. https://doi.org/10.1183/09031936.00020214

De Ruysscher, D., & Slotman, B. (2003). Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. Radiotherapy and Oncology, 68(3), 299-302.

De Wever, W., Stroobants, S., Coolen, J., & Verschakelen, J. A. (2009). Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. European Respiratory Journal, 33(1), 201-212. https://doi.org/10.1183/09031936.00035108

Desai, R., Koipallil, G. K., Thomas, N., Mhaskar, R., Visweshwar, N., Laber, D., . . . Jaglal, M. (2020). Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Scientific Reports, 10(1), 18945. https://doi.org/10.1038/s41598-020-75863-3

Detterbeck, F. C. (2010). Management of carcinoid tumors. Annals of Thoracic Surgery, 89(3), 998-1005. https://doi.org/10.1016/j.athoracsur.2009.07.097

Detterbeck, F. C., Nicholson, A. G., Franklin, W. A., Marom, E. M., Travis, W. D., Girard, N., . . . Participating Institutions. (2016). The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 11(5), 639-650. https://doi.org/10.1016/j.jtho.2016.01.024

Detterbeck, F. C., Nicholson, A. G., Kondo, K., Van Schil, P., & Moran, C. (2011). The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. Journal of Thoracic Oncology, 6(7 Suppl 3), S1710-1716. https://doi.org/10.1097/JTO.0b013e31821e8cff

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., . . . trial investigators. (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncology, 21(2), 271-282. https://doi.org/10.1016/S1470-2045(19)30691-6

Doebele, R. C., Perez, L., Trinh, H., Martinec, M., Martina, R., Riehl, T., . . . Crane, G. (2021). Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in. Journal of comparative effectiveness research, 10(17), 1271-1282. https://doi.org/10.2217/cer-2021-0131

Dominioni, L., Rotolo, N., Mantovani, W., Poli, A., Pisani, S., Conti, V., . . . Imperatori, A. (2012). A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up. BMC Cancer, 12, 18. https://doi.org/10.1186/1471-2407-12-18

Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., . . . trial investigators. (2020). Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncology, 21(2), 261-270. https://doi.org/10.1016/S1470-2045(19)30690-4

Drilon, A., Siena, S., Ou, S. I., Patel, M., Ahn, M. J., Lee, J., . . . De Braud, F. G. (2017). Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 7(4), 400-409. https://doi.org/10.1158/2159-8290.CD-16-1237

Du Rand, I. A., Barber, P. V., Goldring, J., Lewis, R. A., Mandal, S., Munavvar, M., . . . British Thoracic Society Interventional Bronchoscopy Guideline Group. (2011). British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax, 66 Suppl 3, iii1-21. https://doi.org/10.1136/thoraxjnl-2011-200713

Dziadziuszko, R., Krebs, M. G., De Braud, F., Siena, S., Drilon, A., Doebele, R. C., . . . Barlesi, F. (2021). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic. Journal of Clinical Oncology, 39(11), 1253-1263. https://doi.org/10.1200/JCO.20.03025

Eblan, M. J., Corradetti, M. N., Lukens, J. N., Xanthopoulos, E., Mitra, N., Christodouleas, J. P., . . . Apisarnthanarax, S. (2013). Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications. International Journal of Radiation Oncology, Biology, Physics, 85(1), 175-181. https://doi.org/10.1016/j.ijrobp.2012.03.051

Edvardsen, E., Skjønsberg, O. H., Holme, I., Nordsletten, L., Borchsenius, F., & Anderssen, S. A. (2015). High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax, 70(3), 244-250. https://doi.org/10.1136/thoraxjnl-2014-205944

Eguren-Santamaria, I., Sanmamed, M. F., Goldberg, S. B., Kluger, H. M., Idoate, M. A., Lu, B. Y., . . . Gil-Bazo, I. (2020). PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research, 26(16), 4186-4197. https://doi.org/10.1158/1078-0432.CCR-20-0798

Eide, I. J. Z., Stensgaard, S., Helland, Å., Ekman, S., Mellemgaard, A., Hansen, K. H., . . . Brustugun, O. T. (2022). Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. Translational lung cancer research, 11(6), 953-963. https://doi.org/10.21037/tlcr-21-995

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . . Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228-247. https://doi.org/10.1016/j.ejca.2008.10.026

Ellis, P., Davies, A. M., Evans, W. K., Haynes, A. E., Lloyd, N. S., & Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. (2006). The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. Journal of Thoracic Oncology, 1(6), 591-601.

Ernst, A., Feller-Kopman, D., Becker, H. D., & Mehta, A. C. (2004). Central airway obstruction. American Journal of Respiratory and Critical Care Medicine, 169(12), 1278-1297.

Eze, C., Käsmann, L., & Manapov, F. (2019). Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer. JAMA oncology, 5(1), 11-12. https://doi.org/10.1001/jamaoncol.2018.4833

Fairchild, A., Harris, K., Barnes, E., Wong, R., Lutz, S., Bezjak, A., . . . Chow, E. (2008). Palliative thoracic radiotherapy for lung cancer: a systematic review. Journal of Clinical Oncology, 26(24), 4001-4011.

Falcoz, P. E., Puyraveau, M., Thomas, P. A., Decaluwe, H., Hürtgen, M., Petersen, R. H., . . . ESTS Database Committee and ESTS Minimally Invasive Interest Group. (2015). Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezv154

Falk, S. J., Girling, D. J., White, R. J., Hopwood, P., Harvey, A., Qian, W., & Stephens, R. J. (2002). Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ, 325(7362), 465-465.

Falkson, C. B., Bezjak, A., Darling, G., Gregg, R., Malthaner, R., Maziak, D. E., . . . Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. (2009). The management of thymoma: a systematic review and practice guideline. Journal of Thoracic Oncology, 4(7), 911-919.

Falkson, C. B., Vella, E. T., Ellis, P. M., Maziak, D. E., Ung, Y. C., & Yu, E. (2022). Surgical, Radiation, and Systemic Treatments of Patients with Thymic Epithelial Tumours: A Clinical Practice Guideline. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2022.08.007

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., . . . POPLAR Study Group. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387(10030), 1837-1846. https://doi.org/10.1016/S0140-6736(16)00587-0

Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., . . . IMpower010 Investigators. (2021). Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. https://doi.org/10.1016/S0140-6736(21)02098-5

Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., . . . CONFIRM trial investigators. (2021). Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncology, 22(11), 1530-1540. https://doi.org/10.1016/S1470-2045(21)00471-X

Ferguson, M. K., & Lehman, A. G. (2003). Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Annals of Thoracic Surgery, 76(6), 1782-1788.

Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer. https://doi.org/10.1002/ijc.33588

Fernandez-Cuesta, L., Peifer, M., Lu, X., Sun, R., Ozretić, L., Seidel, D., . . . Thomas, R. K. (2014). Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature communications, 5, 3518. https://doi.org/10.1038/ncomms4518

Ferrara, M. G., Stefani, A., Simbolo, M., Pilotto, S., Martini, M., Lococo, F., . . . Bria, E. (2021). Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. Frontiers in Oncology, 11, 650293. https://doi.org/10.3389/fonc.2021.650293

Ferris, F. D., Bruera, E., Cherny, N., Cummings, C., Currow, D., Dudgeon, D., . . . Von Roenn, J. H. (2009). Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. Journal of Clinical Oncology, 27(18), 3052-3058. https://doi.org/10.1200/JCO.2008.20.1558

Filosso, P. L., Oliaro, A., Ruffini, E., Bora, G., Lyberis, P., Asioli, S., . . . Guerrera, F. (2013). Outcome and prognostic factors in bronchial carcinoids: a single-center experience. Journal of Thoracic Oncology, 8(10), 1282-1288. https://doi.org/10.1097/JTO.0b013e31829f097a

Filosso, P. L., Yao, X., Ruffini, E., Ahmad, U., Antonicelli, A., Huang, J., . . . Korst, R. (2016). Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. European Journal of Cardio-Thoracic Surgery, 50(4), 766-771. https://doi.org/10.1093/ejcts/ezw107

Fink, G., Krelbaum, T., Yellin, A., Bendayan, D., Saute, M., Glazer, M., & Kramer, M. R. (2001). Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest, 119(6), 1647-1651.

Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E., Fleischmann, K. E., . . . Society for Vascular Surgery. (2007). ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation, 116(17), e418-499. https://doi.org/10.1161/CIRCULATIONAHA.107.185699

Fogh, S., & Yom, S. S. (2014). Symptom management during the radiation oncology treatment course: a practical guide for the oncology clinician. Seminars in Oncology, 41(6), 764-775. https://doi.org/10.1053/j.seminoncol.2014.09.020

Foster, C. C., Rusthoven, C. G., Sher, D. J., Feldman, L., Pasquinelli, M., Spiotto, M. T., & Koshy, M. (2019). Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis. Lung Cancer, 130, 162-168. https://doi.org/10.1016/j.lungcan.2019.02.023

Francis, S., Orton, A., Stoddard, G., Tao, R., Hitchcock, Y. J., Akerley, W., & Kokeny, K. E. (2017). Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, JCO2017744771. https://doi.org/10.1200/JCO.2017.74.4771

Fruh, M., Rolland, E., Pignon, J.-P., Seymour, L., Ding, K., Tribodet, H., . . . Shepherd, F. A. (2008). Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. Journal of Clinical Oncology, 26(21), 3573-3581.

Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., Felip, E., & ESMO Guidelines Working Group. (2013). Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24 Suppl 6, vi99-105. https://doi.org/10.1093/annonc/mdt178

Fujii, Y. (2011). Published guidelines for management of thymoma. Thoracic Surgery Clinics, 21(1), 125-129, viii. https://doi.org/10.1016/j.thorsurg.2010.08.002

Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., . . . Garassino, M. C. (2020). Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38(14), 1505-1517. https://doi.org/10.1200/JCO.19.03136

Gadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., . . . Ou, S. I. (2016). Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 34(34), 4079-4085. https://doi.org/10.1200/JCO.2016.68.4639

Gandhi, L., & Garassino, M. C. (2018). Pembrolizumab plus Chemotherapy in Lung Cancer. New England Journal of Medicine, 379(11), e18. https://doi.org/10.1056/NEJMc1808567

Garassino, M. C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., . . . Faivre-Finn, C. (2022). Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2022.07.1148

Garon, E. B., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., . . . Pérol, M. (2014). Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 384(9944), 665-673. https://doi.org/10.1016/S0140-6736(14)60845-X

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., . . . KEYNOTE-001 Investigators. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. New England Journal of Medicine, 372(21), 2018-2028. https://doi.org/10.1056/NEJMoa1501824

Genova, C., Rijavec, E., & Grossi, F. (2016). Hematopoietic growth factors in lung cancer. Current Opinion in Oncology, 28(2), 135-144. https://doi.org/10.1097/CCO.0000000000000268

George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F., . . . Thomas, R. K. (2018). Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature communications, 9(1), 1048. https://doi.org/10.1038/s41467-018-03099-x

George, R., Jeba, J., Ramkumar, G., Chacko, A. G., & Tharyan, P. (2015). Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database of Systematic Reviews, (9), CD006716. https://doi.org/10.1002/14651858.CD006716.pub3

Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., . . . Brahmer, J. (2018). Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology, 36(17), 1675-1684. https://doi.org/10.1200/JCO.2017.77.0412

Girard, N., Ruffini, E., Marx, A., Faivre-Finn, C., Peters, S., & ESMO Guidelines Committee. (2015). Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26 Suppl 5, v40-55. https://doi.org/10.1093/annonc/mdv277

Godoy, M. C., & Naidich, D. P. (2012). Overview and strategic management of subsolid pulmonary nodules. Journal of Thoracic Imaging, 27(4), 240-248. https://doi.org/10.1097/RTI.0b013e31825d515b

Goeckenjan, G., Sitter, H., Thomas, M., Branscheid, D., Flentje, M., Griesinger, F., . . . German Cancer Society. (2011). Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie, 65(1), 39-59. https://doi.org/10.1055/s-0030-1255961

Gollard, R., Jhatakia, S., Elliott, M., & Kosty, M. (2010). Large cell/neuroendocrine carcinoma. Lung Cancer, 69(1), 13-18. https://doi.org/10.1016/j.lungcan.2009.12.011

Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Lee, J. J., . . . Heymach, J. V. (2019). Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 37(18), 1558-1565. https://doi.org/10.1200/JCO.19.00201

Gorenberg, M., Bar-Shalom, R., & Israel, O. (2008). Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. British Journal of Radiology, 81(970), 821-825. https://doi.org/10.1259/bjr/26210052

Gould, M. K., Donington, J., Lynch, W. R., Mazzone, P. J., Midthun, D. E., Naidich, D. P., & Wiener, R. S. (2013). Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e93S-120S. https://doi.org/10.1378/chest.12-2351

Granberg, D., Eriksson, B., Wilander, E., Grimfjärd, P., Fjällskog, M. L., Oberg, K., & Skogseid, B. (2001). Experience in treatment of metastatic pulmonary carcinoid tumors. Annals of Oncology, 12(10), 1383-1391.

Grassi, L., Nanni, M. G., Rodin, G., Li, M., & Caruso, R. (2018). The use of antidepressants in oncology: a review and practical tips for oncologists. Annals of Oncology, 29(1), 101-111. https://doi.org/10.1093/annonc/mdx526

Gray, S. G., & Mutti, L. (2020). Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Translational lung cancer research, 9(Suppl 1), S100-S119. https://doi.org/10.21037/tlcr.2019.11.23

Gridelli, C., Ardizzoni, A., Ciardiello, F., Hanna, N., Heymach, J. V., Perrone, F., . . . De Marinis, F. (2008). Second-line treatment of advanced non-small cell lung cancer. Journal of Thoracic Oncology, 3(4), 430-440.

Griffin, A. C., Schwartz, L. E., & Baloch, Z. W. (2011). Utility of on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspiration specimens. Cytojournal, 8, 20. https://doi.org/10.4103/1742-6413.90081

Gronberg, B. H., Bremnes, R. M., Flotten, O., Amundsen, T., Brunsvig, P. F., Hjelde, H. H., . . . Sundstrom, S. (2009). Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 27(19), 3217-3224.

Groome, P. A., Bolejack, V., Crowley, J. J., Kennedy, C., Krasnik, M., Sobin, L. H., & Goldstraw, P. (2007). The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. Journal of Thoracic Oncology, 2(8), 694-705.

Grønberg, B. H., Halvorsen, T. O., Fløtten, Ø., Brustugun, O. T., Brunsvig, P. F., Aasebø, U., . . . Norwegian Lung Cancer Study Group. (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncologica, 55(5), 591-597. https://doi.org/10.3109/0284186X.2015.1092584

Grønberg, B. H., Killingberg, K. T., Fløtten, Ø., Brustugun, O. T., Hornslien, K., Madebo, T., . . . Halvorsen, T. O. (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncology, 22(3), 321-331. https://doi.org/10.1016/S1470-2045(20)30742-7

Guckenberger, M., Mantel, F., Gerszten, P. C., Flickinger, J. C., Sahgal, A., Létourneau, D., . . . Kersh, R. (2014). Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiation Oncology (London, England), 9, 226. https://doi.org/10.1186/s13014-014-0226-2

Guerra, L., De Ponti, E., Elisei, F., Bettinardi, V., Landoni, C., Picchio, M., . . . Messa, C. (2012). Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. European Journal of Nuclear Medicine and Molecular Imaging, 39(9), 1381-1390. https://doi.org/10.1007/s00259-012-2148-2

Guisier, F., Dubos-Arvis, C., Viñas, F., Doubre, H., Ricordel, C., Ropert, S., . . . Bylicki, O. (2020). Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology, 15(4), 628-636. https://doi.org/10.1016/j.jtho.2019.12.129

Gulstene, S., Ruwanpura, T., Palma, D., & Joseph, N. (2022). Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal? Clinical Oncology (Royal College of Radiologists), 34(11), 733-740. https://doi.org/10.1016/j.clon.2022.08.027

Gunluoglu, M. Z., Melek, H., Medetoglu, B., Demir, A., Kara, H. V., & Dincer, S. I. (2011). The validity of preoperative lymph node staging guidelines of European Society of Thoracic Surgeons in non-small-cell lung cancer patients. European Journal of Cardio-Thoracic Surgery, 40(2), 287-290. https://doi.org/10.1016/j.ejcts.2010.11.030

Ha, D., Mazzone, P. J., Ries, A. L., Malhotra, A., & Fuster, M. (2016). The Utility of Exercise Testing in Patients with Lung Cancer. Journal of Thoracic Oncology, 11(9), 1397-1410. https://doi.org/10.1016/j.jtho.2016.04.021

Hallifax, R. J., Talwar, A., Wrightson, J. M., Edey, A., & Gleeson, F. V. (2017). State-of-the-art: Radiological investigation of pleural disease. Respiratory Medicine, 124, 88-99. https://doi.org/10.1016/j.rmed.2017.02.013

Hamaji, M., Kojima, F., Omasa, M., Sozu, T., Sato, T., Chen, F., . . . Date, H. (2015). A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. European Journal of Cardio-Thoracic Surgery, 47(4), 602-607. https://doi.org/10.1093/ejcts/ezu277

Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Remy, J. (2008). Fleischner Society: glossary of terms for thoracic imaging. Radiology, 246(3), 697-722. https://doi.org/10.1148/radiol.2462070712

Haratake, N., & Seto, T. (2021). NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy. Clinical Lung Cancer, 22(1), 1-5. https://doi.org/10.1016/j.cllc.2020.10.013

Harpole, D. H., Feldman, J. M., Buchanan, S., Young, W. G., & Wolfe, W. G. (1992). Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Annals of Thoracic Surgery, 54(1), 50-54; discussion 54-55.

Hassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gulsuner, S., . . . Churpek, J. E. (2019). Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 116(18), 9008-9013. https://doi.org/10.1073/pnas.1821510116

Helbekkmo, N., Sundstrom, S. H., Aasebo, U., Brunsvig, P. F., von Plessen, C., Hjelde, H. H., . . . Bremnes, R. M. (2007). Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. British Journal of Cancer, 97(3), 283-289. https://doi.org/6603869 [pii] 10.1038/sj.bjc.6603869

Helland, Å., Solberg, S., & Brustugun, O. T. (2012). Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. Journal of Thoracic Oncology, 7(12), 1858-1861. https://doi.org/10.1097/JTO.0b013e318275b346

Hendriks, L. E., Hermans, B. C., van den Beuken-van Everdingen, M. H., Hochstenbag, M. M., & Dingemans, A. M. (2016). Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. Journal of Thoracic Oncology, 11(2), 155-173. https://doi.org/10.1016/j.jtho.2015.10.001

Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Pérez-Gracia, J. L., Han, J. Y., . . . Garon, E. B. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387(10027), 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7

Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., . . . Spigel, D. R. (2020). Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. New England Journal of Medicine, 383(14), 1328-1339. https://doi.org/10.1056/NEJMoa1917346

Herder, G. J., van Tinteren, H., Golding, R. P., Kostense, P. J., Comans, E. F., Smit, E. F., & Hoekstra, O. S. (2005). Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest, 128(4), 2490-2496. https://doi.org/10.1378/chest.128.4.2490

Hermes, A., Bergman, B., Bremnes, R., Ek, L., Fluge, S., Sederholm, C., . . . Sorenson, S. (2008). Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. Journal of Clinical Oncology, 26(26), 4261-4267.

Herth, F., Becker, H. D., & Ernst, A. (2004). Conventional vs endobronchial ultrasound-guided transbronchial needle aspiration: a randomized trial. Chest, 125(1), 322-325.

Herth, F. J., Eberhardt, R., Krasnik, M., & Ernst, A. (2008). Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest, 133(4), 887-891. https://doi.org/10.1378/chest.07-2535

Herth, F. J., Ernst, A., Eberhardt, R., Vilmann, P., Dienemann, H., & Krasnik, M. (2006). Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically normal mediastinum. European Respiratory Journal, 28(5), 910-914. https://doi.org/10.1183/09031936.06.00124905

Hillerdal, G., Sorensen, J. B., Sundstrom, S., Riska, H., Vikstrom, A., & Hjerpe, A. (2008). Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. Journal of Thoracic Oncology, 3(11), 1325-1331.

Hishida, T., Nagai, K., Yoshida, J., Nishimura, M., Ishii, G.-i., Iwasaki, M., & Nishiwaki, Y. (2006). Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? Journal of Thoracic and Cardiovascular Surgery, 131(4), 838-842.

Hochmair, M., Weinlinger, C., Schwab, S., Naber, J., Setinek, U., Krenbek, D., . . . Burghuber, O. C. (2019). Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. Anti-Cancer Drugs, 30(7), e0787. https://doi.org/10.1097/CAD.0000000000000787

Hollevoet, K., Reitsma, J. B., Creaney, J., Grigoriu, B. D., Robinson, B. W., Scherpereel, A., . . . van Meerbeeck, J. P. (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. Journal of Clinical Oncology, 30(13), 1541-1549. https://doi.org/10.1200/JCO.2011.39.6671

Holsti, L. R., Pyrhonen, S., Kajanti, M., Mantyla, M., Mattson, K., Maasilta, P., & Kivisaari, L. (1997). Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncologica, 36(4), 397-405.

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., . . . Drilon, A. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncology, 21(4), 531-540. https://doi.org/10.1016/S1470-2045(19)30856-3

Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., . . . IMpower133 Study Group. (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379(23), 2220-2229. https://doi.org/10.1056/NEJMoa1809064

Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004). Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 22(19), 3852-3859. https://doi.org/10.1200/JCO.2004.02.109

Huang, J., Detterbeck, F. C., Wang, Z., & Loehrer, P. J. (2011). Standard outcome measures for thymic malignancies. Journal of Thoracic Oncology, 6(7 Suppl 3), S1691-1697. https://doi.org/10.1097/JTO.0b013e3182254ac1

Huber, R. M., Hansen, K. H., Paz-Ares Rodríguez, L., West, H. L., Reckamp, K. L., Leighl, N. B., . . . Camidge, D. R. (2020). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology, 15(3), 404-415. https://doi.org/10.1016/j.jtho.2019.11.004

Hui, D., & Bruera, E. (2016). Integrating palliative care into the trajectory of cancer care. Nature Reviews: Clinical Oncology, 13(3), 159-171. https://doi.org/10.1038/nrclinonc.2015.201

Ignatius Ou, S. H., & Zell, J. A. (2009). The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. Journal of Thoracic Oncology, 4(3), 300-310. https://doi.org/10.1097/JTO.0b013e318194a355

Iyoda, A., Hiroshima, K., Moriya, Y., Iwadate, Y., Takiguchi, Y., Uno, T., . . . Yoshino, I. (2009). Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. Journal of Thoracic and Cardiovascular Surgery, 138(2), 446-453. https://doi.org/10.1016/j.jtcvs.2008.12.037

Jakopovic, M., Bitar, L., Seiwerth, F., Marusic, A., Krpina, K., & Samarzija, M. (2020). Immunotherapy for thymoma. Journal of Thoracic Disease, 12(12), 7635-7641. https://doi.org/10.21037/jtd-2019-thym-12

Janni, W., Kiechle, M., Sommer, H., Rack, B., Gauger, K., Heinrigs, M., . . . ADEBAR Study Group. (2006). Study participation improves treatment strategies and individual patient care in participating centers. Anticancer Research, 26(5B), 3661-3667.

Jennings, A. L., Davies, A. N., Higgins, J. P., Gibbs, J. S., & Broadley, K. E. (2002). A systematic review of the use of opioids in the management of dyspnoea. Thorax, 57(11), 939-944. https://doi.org/10.1136/thorax.57.11.939

Jensen, L. H., Osterlind, K., & Rytter, C. (2008). Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer, 62(1), 85-91.

Johnson, D. B., Chandra, S., & Sosman, J. A. (2018). Immune Checkpoint Inhibitor Toxicity in 2018. JAMA, 320(16), 1702-1703. https://doi.org/10.1001/jama.2018.13995

Johnson, M. L., De Langen, J., Waterhouse, D. M., Mazieres, J., Dingemans, A. C., Mountzios, G., . . . Paz-Ares, L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Annals of Oncology, 33, S808-S869.

Johnson, P. T., Horton, K. M., & Fishman, E. K. (2009). Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics, 29(5), 1333-1351. https://doi.org/10.1148/rg.295095027

Kadota, K., Suzuki, K., Colovos, C., Sima, C. S., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2012). A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Modern Pathology, 25(2), 260-271. https://doi.org/10.1038/modpathol.2011.146

Kann, B. H., Miccio, J. A., Stahl, J. M., Ross, R., Verma, V., Dosoretz, A. P., . . . Decker, R. H. (2019). Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiotherapy and Oncology, 132, 188-196. https://doi.org/10.1016/j.radonc.2018.10.017

Kantor, T., & Wakeam, E. (2021). Landmark Trials in the Surgical Management of Mesothelioma. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-021-09589-5

Kauczor, H. U., Bonomo, L., Gaga, M., Nackaerts, K., Peled, N., Prokop, M., . . . European Respiratory Society (ERS). (2015). ESR/ERS white paper on lung cancer screening. European Respiratory Journal, 46(1), 28-39. https://doi.org/10.1183/09031936.00033015

Kelly, R. J., Sharon, E., & Hassan, R. (2011). Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer, 73(3), 256-263. https://doi.org/10.1016/j.lungcan.2011.04.014

Kenmotsu, H., Yamamoto, N., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., . . . Tsuboi, M. (2020). Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38(19), 2187-2196. https://doi.org/10.1200/JCO.19.02674

Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. (2019). Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. Journal of the National Comprehensive Cancer Network, 17(6), 750-757. https://doi.org/10.6004/jnccn.2019.7310

Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., Camidge, D. R., . . . Shaw, A. T. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncology. https://doi.org/10.1016/S1470-2045(15)00614-2

Kim, D. W., Tiseo, M., Ahn, M. J., Reckamp, K. L., Hansen, K. H., Kim, S. W., . . . Camidge, D. R. (2017). Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 35(22), 2490-2498. https://doi.org/10.1200/JCO.2016.71.5904

Kodama, K., Doi, O., Higashiyama, M., & Yokouchi, H. (1997). Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: a single-institution study. Journal of Thoracic and Cardiovascular Surgery, 114(3), 347-353.

Komaki, R., & Gomez, D. R. (2014). Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive. Frontiers in Oncology, 3, 330. https://doi.org/10.3389/fonc.2013.00330

Komiya, T., Ravindra, N., & Powell, E. (2021). Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung. Asian Pacific Journal of Cancer Prevention, 22(2), 365-370. https://doi.org/10.31557/APJCP.2021.22.2.365

Konge, L., Vilmann, P., Clementsen, P., Annema, J. T., & Ringsted, C. (2012). Reliable and valid assessment of competence in endoscopic ultrasonography and fine-needle aspiration for mediastinal staging of non-small cell lung cancer. Endoscopy, 44(10), 928-933. https://doi.org/10.1055/s-0032-1309892

Korse, C. M., Taal, B. G., Vincent, A., van Velthuysen, M. L., Baas, P., Buning-Kager, J. C., . . . Bonfrer, J. M. (2012). Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. European Journal of Cancer, 48(5), 662-671. https://doi.org/10.1016/j.ejca.2011.08.012

Korst, R. J., Bezjak, A., Blackmon, S., Choi, N., Fidias, P., Liu, G., . . . Keshavjee, S. (2014). Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. Journal of Thoracic and Cardiovascular Surgery, 147(1), 36-44, 46.e31. https://doi.org/10.1016/j.jtcvs.2013.08.061

Kozower, B. D., Larner, J. M., Detterbeck, F. C., & Jones, D. R. (2013). Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e369S-e399S. https://doi.org/10.1378/chest.12-2362

Kreuter, M., Vansteenkiste, J., Fischer, J. R., Eberhardt, W., Zabeck, H., Kollmeier, J., . . . TREAT investigators. (2013). Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Annals of Oncology, 24(4), 986-992. https://doi.org/10.1093/annonc/mds578

Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., . . . Vogelzang, N. J. (2009). Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. Journal of Clinical Oncology, 27(18), 3007-3013. https://doi.org/10.1200/JCO.2008.20.3943

Kulke, M. H., Lenz, H. J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., . . . Fuchs, C. S. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 26(20), 3403-3410. https://doi.org/10.1200/JCO.2007.15.9020

Kumar, A., Weber, M. H., Gokaslan, Z., Wolinsky, J. P., Schmidt, M., Rhines, L., . . . Fisher, C. G. (2017). Metastatic Spinal Cord Compression and Steroid Treatment: A Systematic Review. Clinical spine surgery, 30(4), 156-163. https://doi.org/10.1097/BSD.0000000000000528

Kaasa, S., Loge, J. H., Aapro, M., Albreht, T., Anderson, R., Bruera, E., . . . Lundeby, T. (2018). Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncology, 19(11), e588-e653. https://doi.org/10.1016/S1470-2045(18)30415-7

Lad, T., Piantadosi, S., Thomas, P., Payne, D., Ruckdeschel, J., & Giaccone, G. (1994). A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest, 106(6 Suppl), 320S-323S.

Lakha, S., Gomez, J. E., Flores, R. M., & Wisnivesky, J. P. (2014). Prognostic significance of visceral pleural involvement in early-stage lung cancer. Chest, 146(6), 1619-1626. https://doi.org/10.1378/chest.14-0204

Lamba, N., Muskens, I. S., DiRisio, A. C., Meijer, L., Briceno, V., Edrees, H., . . . Broekman, M. L. (2017). Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiation Oncology (London, England), 12(1), 106. https://doi.org/10.1186/s13014-017-0840-x

Le Péchoux, C., Dunant, A., Senan, S., Wolfson, A., Quoix, E., Faivre-Finn, C., . . . Prophylactic Cranial Irradiation (PCI) Collaborative Group. (2009). Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncology, 10(5), 467-474. https://doi.org/10.1016/S1470-2045(09)70101-9

Le Péchoux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R., Lerouge, D., . . . Prophylactic Cranial Irradiation (PCI) Collaborative Group. (2011). Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology, 22(5), 1154-1163. https://doi.org/10.1093/annonc/mdq576

Le Treut, J., Sault, M. C., Lena, H., Souquet, P. J., Vergnenegre, A., Le Caer, H., . . . Chouaid, C. (2013). Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Annals of Oncology, 24(6), 1548-1552. https://doi.org/10.1093/annonc/mdt009

Lee, H. S., Lee, G. K., Kim, M. S., Lee, J. M., Kim, H. Y., Nam, B. H., . . . Hwangbo, B. (2008). Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station? Chest, 134(2), 368-374. https://doi.org/10.1378/chest.07-2105

Lee, T. H., Marcantonio, E. R., Mangione, C. M., Thomas, E. J., Polanczyk, C. A., Cook, E. F., . . . Goldman, L. (1999). Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation, 100(10), 1043-1049.

Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., . . . Awad, M. M. (2018). Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. Journal of Clinical Oncology, 36(19), 1905-1912. https://doi.org/10.1200/JCO.2017.77.0305

Li, A., Garcia, D. A., Lyman, G. H., & Carrier, M. (2019). Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thrombosis Research, 173, 158-163. https://doi.org/10.1016/j.thromres.2018.02.144

Liao, Z., Lee, J. J., Komaki, R., Gomez, D. R., O'Reilly, M. S., Fossella, F. V., . . . Mohan, R. (2018). Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36(18), 1813-1822. https://doi.org/10.1200/JCO.2017.74.0720

Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., . . . Society for Cardiothoracic Surgery in Great Britain and Ireland. (2010). Guidelines on the radical management of patients with lung cancer. Thorax, 65 Suppl 3, iii1-27. https://doi.org/10.1136/thx.2010.145938

Lim, S. M., Kim, H. R., Lee, J. S., Lee, K. H., Lee, Y. G., Min, Y. J., . . . Cho, B. C. (2017). Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. Journal of Clinical Oncology, 35(23), 2613-2618. https://doi.org/10.1200/JCO.2016.71.3701

Limonnik, V., Abel, S., Finley, G. G., Long, G. S., & Wegner, R. E. (2020). Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis. Lung Cancer, 150, 107-113. https://doi.org/10.1016/j.lungcan.2020.10.001

Lindberg, K., Grozman, V., Karlsson, K., Lindberg, S., Lax, I., Wersäll, P., . . . Lewensohn, R. (2021). The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. Journal of Thoracic Oncology, 16(7), 1200-1210. https://doi.org/10.1016/j.jtho.2021.03.019

Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., . . . Garon, E. B. (2018). A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. Journal of Thoracic Oncology, 13(8), 1138-1145. https://doi.org/10.1016/j.jtho.2018.03.035

Liu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., . . . Borczuk, A. C. (2015). Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2015.62.0674

Lock, M. I., Hoyer, M., Bydder, S. A., Okunieff, P., Hahn, C. A., Vichare, A., & Dawson, L. A. (2012). An international survey on liver metastases radiotherapy. Acta Oncologica, 51(5), 568-574. https://doi.org/10.3109/0284186X.2012.681700

Loehrer, P. J., Wang, W., Johnson, D. H., Aisner, S. C., Ettinger, D. S., & Eastern Cooperative Oncology Group Phase II Trial. (2004). Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. Journal of Clinical Oncology, 22(2), 293-299. https://doi.org/10.1200/JCO.2004.02.047

Lou, F., Huang, J., Sima, C. S., Dycoco, J., Rusch, V., & Bach, P. B. (2013). Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. Journal of Thoracic and Cardiovascular Surgery, 145(1), 75-81; discussion 81-72. https://doi.org/10.1016/j.jtcvs.2012.09.030

Louw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., van Vliet, C., . . . Røe, O. D. (2022). BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. Journal of Thoracic Oncology, 17(7), 921-930. https://doi.org/10.1016/j.jtho.2022.04.008

Lund-Iversen, M., Grøholt, K. K., Helland, Å., Borgen, E., & Brustugun, O. T. (2015). NUT expression in primary lung tumours. Diagnostic Pathology, 10, 156. https://doi.org/10.1186/s13000-015-0395-9

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., . . . Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129-2139.

Mackley, H. B., & Videtic, G. M. (2006). Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park, N.Y.), 20(12), 1537-1543; discussion 1544-1535, 1549.

MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., . . . Bankier, A. A. (2017). Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 284(1), 228-243. https://doi.org/10.1148/radiol.2017161659

MacManus, M., Nestle, U., Rosenzweig, K. E., Carrio, I., Messa, C., Belohlavek, O., . . . Jeremic, B. (2009). Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiotherapy and Oncology, 91(1), 85-94.

Manhire, A., Charig, M., Clelland, C., Gleeson, F., Miller, R., Moss, H., . . . BTS. (2003a). Guidelines for radiologically guided lung biopsy. Thorax, 58(11), 920-936.

Manhire, A. R., Richardson, C. M., & Gleeson, F. V. (2003b). Lung biopsy guidelines--for the obedience of fools and guidance of wise men. Thorax, 58(11), 913-914.

Manohar, S., Thongprayoon, C., Cheungpasitporn, W., Markovic, S. N., & Herrmann, S. M. (2020). Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney international reports, 5(2), 149-158. https://doi.org/10.1016/j.ekir.2019.11.015

Mao, J., Kocak, Z., Zhou, S., Garst, J., Evans, E. S., Zhang, J., . . . Marks, L. B. (2007). The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. International Journal of Radiation Oncology, Biology, Physics, 67(5), 1360-1369. https://doi.org/10.1016/j.ijrobp.2006.11.003

Marinaccio, A., Binazzi, A., Cauzillo, G., Cavone, D., Zotti, R. D., Ferrante, P., . . . Tumino, R. (2007). Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. European Journal of Cancer, 43(18), 2722-2728. https://doi.org/S0959-8049(07)00748-4 [pii] 10.1016/j.ejca.2007.09.018

Marom, E. M. (2013). Advances in thymoma imaging. Journal of Thoracic Imaging, 28(2), 69-80; quiz 81-63. https://doi.org/10.1097/RTI.0b013e31828609a0

Martinou, M., & Gaya, A. (2013). Cardiac complications after radical radiotherapy. Seminars in Oncology, 40(2), 178-185. https://doi.org/10.1053/j.seminoncol.2013.01.007

Marx, A., Chan, J. K. C., Chalabreysse, L., Dacic, S., Detterbeck, F., French, C. A., . . . Ströbel, P. (2022). The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? Journal of Thoracic Oncology, 17(2), 200-213. https://doi.org/10.1016/j.jtho.2021.10.010

Masaoka, A. (2010). Staging system of thymoma. Journal of Thoracic Oncology, 5(10 Suppl 4), S304-312. https://doi.org/10.1097/JTO.0b013e3181f20c05

Massoth, L. R., Hung, Y. P., Dias-Santagata, D., Onozato, M., Shah, N., Severson, E., . . . Williams, E. A. (2020). Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A- MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma. JCO precision oncology, 4. https://doi.org/10.1200/PO.19.00288

Matheos, T., Ram, L., & Canelli, R. (2020). Preoperative Evaluation for Thoracic Surgery. Thoracic Surgery Clinics, 30(3), 241-247. https://doi.org/10.1016/j.thorsurg.2020.04.003

Matsumoto, R., Takamori, S., Yokoyama, S., Hashiguchi, T., Murakami, D., Yoshiyama, K., . . . Akagi, Y. (2018). Lung function in the late postoperative phase and influencing factors in patients undergoing pulmonary lobectomy. Journal of Thoracic Disease, 10(5), 2916-2923. https://doi.org/10.21037/jtd.2018.05.27

McKenna, R. J., Mahtabifard, A., Yap, J., McKenna, R., Fuller, C., Merhadi, A., & Hakimian, B. (2008). Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function. Annals of Thoracic Surgery, 85(2), 733-736.

Mehta, V. (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. International Journal of Radiation Oncology, Biology, Physics, 63(1), 5-24. https://doi.org/10.1016/j.ijrobp.2005.03.047

Mesko, S., & Gomez, D. (2018). Proton Therapy in Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 19(12), 76. https://doi.org/10.1007/s11864-018-0588-z

Moertel, C. G., & Hanley, J. A. (1979). Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials, 2(4), 327-334.

Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 68(2), 227-232.

Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., . . . AURA3 Investigators. (2017). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. New England Journal of Medicine, 376(7), 629-640. https://doi.org/10.1056/NEJMoa1612674

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., . . . Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-957.

Mok, T. S. K., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., . . . KEYNOTE-042 Investigators. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393(10183), 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7

Mollberg, N. M., & Ferguson, M. K. (2013). Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Annals of Thoracic Surgery, 95(3), 1112-1121. https://doi.org/10.1016/j.athoracsur.2012.09.075

Moore, W., Freiberg, E., Bishawi, M., Halbreiner, M. S., Matthews, R., Baram, D., & Bilfinger, T. V. (2013). FDG-PET imaging in patients with pulmonary carcinoid tumor. Clinical Nuclear Medicine, 38(7), 501-505. https://doi.org/10.1097/RLU.0b013e318279f0f5

Mulvenna, P., Nankivell, M., Barton, R., Faivre-Finn, C., Wilson, P., McColl, E., . . . Langley, R. E. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet, 388(10055), 2004-2014. https://doi.org/10.1016/S0140-6736(16)30825-X

Munavvar, M., Khan, M. A., Edwards, J., Waqaruddin, Z., & Mills, J. (2007). The autoclavable semirigid thoracoscope: the way forward in pleural disease? European Respiratory Journal, 29(3), 571-574. https://doi.org/10.1183/09031936.00101706

Naidich, D. P., Bankier, A. A., MacMahon, H., Schaefer-Prokop, C. M., Pistolesi, M., Goo, J. M., . . . Travis, W. D. (2013). Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology, 266(1), 304-317. https://doi.org/10.1148/radiol.12120628

Naidoo, J., Santos-Zabala, M. L., Iyriboz, T., Woo, K. M., Sima, C. S., Fiore, J. J., . . . Pietanza, M. C. (2016). Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer, 17(5), e121-e129. https://doi.org/10.1016/j.cllc.2016.01.003

Nantavithya, C., Gomez, D. R., Wei, X., Komaki, R., Liao, Z., Lin, S. H., . . . Chang, J. Y. (2018). Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 101(3), 558-563. https://doi.org/10.1016/j.ijrobp.2018.02.022

Narayan, S., & Thomas, C. R., Jr. (2006). Multimodality therapy for Pancoast tumor. Nature Clinical Practice: Oncology, 3(9), 484-491.

Neyman, K., Sundset, A., Naalsund, A., Espinoza, A., Solberg, S., Kongerud, J., & Fosse, E. (2012). Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study. Journal of bronchology & interventional pulmonology, 19(1), 29-34. https://doi.org/10.1097/LBR.0b013e3182446b52

Nezu, K., Kushibe, K., Tojo, T., Takahama, M., & Kitamura, S. (1998). Recovery and limitation of exercise capacity after lung resection for lung cancer. Chest, 113(6), 1511-1516.

Ng, T. L., Narasimhan, N., Gupta, N., Venkatakrishnan, K., Kerstein, D., & Camidge, D. R. (2020). Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. Journal of Thoracic Oncology, 15(7), 1190-1199. https://doi.org/10.1016/j.jtho.2020.02.011

Nguyen, Q. N., Chun, S. G., Chow, E., Komaki, R., Liao, Z., Zacharia, R., . . . Lewis, V. O. (2019). Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA oncology. https://doi.org/10.1001/jamaoncol.2019.0192

Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013). Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clinical Cancer Research, 19(14), 3936-3943. https://doi.org/10.1158/1078-0432.CCR-13-0895

Noonan, C. W. (2017). Environmental asbestos exposure and risk of mesothelioma. Annals of translational medicine, 5(11), 234. https://doi.org/10.21037/atm.2017.03.74

Nussbaum, D. P., Speicher, P. J., Gulack, B. C., Hartwig, M. G., Onaitis, M. W., D'Amico, T. A., & Berry, M. F. (2015). Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Annals of Thoracic Surgery, 99(2), 428-434. https://doi.org/10.1016/j.athoracsur.2014.08.030

O'Brien, M. E., Ciuleanu, T. E., Tsekov, H., Shparyk, Y., Cuceviá, B., Juhasz, G., . . . Crofts, T. (2006a). Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. Journal of Clinical Oncology, 24(34), 5441-5447. https://doi.org/10.1200/JCO.2006.06.5821

O'Brien, M. E., Watkins, D., Ryan, C., Priest, K., Corbishley, C., Norton, A., . . . Sayer, R. (2006b). A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Annals of Oncology, 17(2), 270-275. https://doi.org/10.1093/annonc/mdj073

O'Rourke, N., Garcia, J. C., Paul, J., Lawless, C., McMenemin, R., & Hill, J. (2007). A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiotherapy and Oncology, 84(1), 18-22.

Oh, J. R., Seo, J. H., Chong, A., Min, J. J., Song, H. C., Kim, Y. C., & Bom, H. S. (2012). Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 39(6), 925-935. https://doi.org/10.1007/s00259-011-2059-7

Oken, M. M., Hocking, W. G., Kvale, P. A., Andriole, G. L., Buys, S. S., Church, T. R., . . . PLCO Project Team. (2011). Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA, 306(17), 1865-1873. https://doi.org/10.1001/jama.2011.1591

Ou, S. H., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C., Hughes, B., . . . Kim, D. W. (2016). Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology, 34(7), 661-668. https://doi.org/10.1200/jco.2015.63.9443

Ou, S. I., Nishio, M., Ahn, M. J., Mok, T., Barlesi, F., Zhou, C., . . . Kim, E. S. (2022). Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2022.08.018

Owen, D. H., Benner, B., Wei, L., Sukrithan, V., Goyal, A., Zhou, Y., . . . Konda, B. (2022). A phase 2 clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-22-1552

Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., . . . Wakelee, H. A. (2015). Diffuse high intensity PD-L1 staining in thymic epithelial tumors. Journal of Thoracic Oncology, 10(3), 500-508. https://doi.org/10.1097/JTO.0000000000000429

Page, S., Milner-Watts, C., Perna, M., Janzic, U., Vidal, N., Kaudeer, N., . . . O'Brien, M. (2020). Systemic treatment of brain metastases in non-small cell lung cancer. European Journal of Cancer, 132, 187-198. https://doi.org/10.1016/j.ejca.2020.03.006

Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., . . . Le, X. (2020). Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine, 383(10), 931-943. https://doi.org/10.1056/NEJMoa2004407

Palussière, J., Cazayus, M., Cousin, S., Cabart, M., Chomy, F., Catena, V., & Buy, X. (2021). Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence? Current Oncology Reports, 23(7), 81. https://doi.org/10.1007/s11912-021-01072-4

Pancoast, H. (1932). Superior pulmonary sulcus tumor. JAMA, 99, 1391-1396.

Park, C. M., Goo, J. M., Kim, T. J., Lee, H. J., Lee, K. W., Lee, C. H., . . . Im, J. G. (2008). Pulmonary nodular ground-glass opacities in patients with extrapulmonary cancers: what is their clinical significance and how can we determine whether they are malignant or benign lesions? Chest, 133(6), 1402-1409. https://doi.org/10.1378/chest.07-2568

Park, E. A., Goo, J. M., Lee, J. W., Kang, C. H., Lee, H. J., Lee, C. H., . . . Im, J. G. (2009). Efficacy of computer-aided detection system and thin-slab maximum intensity projection technique in the detection of pulmonary nodules in patients with resected metastases. Investigative Radiology, 44(2), 105-113. https://doi.org/10.1097/RLI.0b013e318190fcfc

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., . . . Cho, B. C. (2021). Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 39(30), 3391-3402. https://doi.org/10.1200/JCO.21.00662

Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., . . . Young, B. (2005). Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet, 366(9486), 643-648.

Patel, A., Roshkovan, L., McNulty, S., Alley, E., Torigian, D. A., Nachiappan, A. C., . . . Katz, S. I. (2021a). Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study. Clinical Lung Cancer, 22(3), 210-217.e211. https://doi.org/10.1016/j.cllc.2020.06.002

Patel, N. V., Yu, N. Y., Koroulakis, A., Diwanji, T., Sawant, A., Sio, T. T., & Mohindra, P. (2021b). Proton therapy for thoracic malignancies: a review of oncologic outcomes. Expert Review of Anticancer Therapy, 21(2), 177-191. https://doi.org/10.1080/14737140.2021.1844567

Patel, S. H., Robbins, J. R., Gore, E. M., Bradley, J. D., Gaspar, L. E., Germano, I., . . . Expert Panel on Radiation Oncology–Brain Metastases. (2012). ACR Appropriateness Criteria® follow-up and retreatment of brain metastases. American Journal of Clinical Oncology, 35(3), 302-306. https://doi.org/10.1097/COC.0b013e31824be246

Payne, C., Larkin, P. J., McIlfatrick, S., Dunwoody, L., & Gracey, J. H. (2013). Exercise and nutrition interventions in advanced lung cancer: a systematic review. Current Oncology (Toronto, Ont.), 20(4), e321-337. https://doi.org/10.3747/co.20.1431

Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., . . . CASPIAN investigators. (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, 394(10212), 1929-1939. https://doi.org/10.1016/S0140-6736(19)32222-6

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., . . . KEYNOTE-407 Investigators. (2018). Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 379(21), 2040-2051. https://doi.org/10.1056/NEJMoa1810865

Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., . . . Halmos, B. (2020). A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 15(10), 1657-1669. https://doi.org/10.1016/j.jtho.2020.06.015

Pedersen, J. H., Sørensen, J. B., Saghir, Z., Fløtten, Ø., Brustugun, O. T., Ashraf, H., . . . Gudbjartsson, T. (2017). Implementation of lung cancer CT screening in the Nordic countries. Acta Oncologica, 56(10), 1249-1257. https://doi.org/10.1080/0284186X.2017.1329592

Pelayo Alvarez, M., Gallego Rubio, O., Bonfill Cosp, X., & Agra Varela, Y. (2009). Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews, (4), CD001990. https://doi.org/10.1002/14651858.CD001990.pub2

Perigaud, C., Bridji, B., Roussel, J. C., Sagan, C., Mugniot, A., Duveau, D., . . . Despins, P. (2009). Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 36(4), 731-736. https://doi.org/10.1016/j.ejcts.2009.05.044

Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D. W., . . . ALEX Trial Investigators. (2017). Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1704795

Pignon, J. P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., . . . Lebeau, B. (1992). A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New England Journal of Medicine, 327(23), 1618-1624.

Pijls-Johannesma, M. C. G., De Ruysscher, D., Lambin, P., Rutten, I., & Vansteenkiste, J. F. (2005). Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database of Systematic Reviews, (1).

Planchard, D., Besse, B., Groen, H. J., Souquet, P. J., Quoix, E., Baik, C. S., . . . Johnson, B. E. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncology, 17(7), 984-993. https://doi.org/10.1016/S1470-2045(16)30146-2

Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., . . . Johnson, B. E. (2017). Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncology, 18(10), 1307-1316. https://doi.org/10.1016/S1470-2045(17)30679-4

Polanski, J., Jankowska-Polanska, B., Rosinczuk, J., Chabowski, M., & Szymanska-Chabowska, A. (2016). Quality of life of patients with lung cancer. OncoTargets and Therapy, 9, 1023-1028. https://doi.org/10.2147/OTT.S100685

Poldermans, D., Bax, J. J., Boersma, E., De Hert, S., Eeckhout, E., Fowkes, G., . . . European Society of Anaesthesiology (ESA). (2010). Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). European Journal of Anaesthesiology, 27(2), 92-137. https://doi.org/10.1097/EJA.0b013e328334c017

Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., . . . Stahel, R. A. (2020). A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of Oncology, 31(12), 1734-1745. https://doi.org/10.1016/j.annonc.2020.09.009

Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., . . . ESMO Guidelines Committee. (2017). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28(suppl_4), iv1-iv21. https://doi.org/10.1093/annonc/mdx222

Pozzessere, C., Lazor, R., Jumeau, R., Peters, S., Prior, J. O., & Beigelman-Aubry, C. (2021). Imaging Features of Pulmonary Immune-related Adverse Events. Journal of Thoracic Oncology, 16(9), 1449-1460. https://doi.org/10.1016/j.jtho.2021.05.017

Prelaj, A., Pircher, C. C., Massa, G., Martelli, V., Corrao, G., Lo Russo, G., . . . Rebuzzi, S. E. (2021). Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers, 13(6). https://doi.org/10.3390/cancers13061300

Pujol, J. L., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Uwer, L., Hureaux, J., . . . Souquet, P. J. (2019). A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. Journal of Thoracic Oncology, 14(5), 903-913. https://doi.org/10.1016/j.jtho.2019.01.008

Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., . . . Cancer Genome Atlas Network. (2018). The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 33(2), 244-258.e210. https://doi.org/10.1016/j.ccell.2018.01.003

Rajan, A., Carter, C. A., Berman, A., Cao, L., Kelly, R. J., Thomas, A., . . . Giaccone, G. (2014). Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncology, 15(2), 191-200. https://doi.org/10.1016/S1470-2045(13)70596-5

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., . . . FLAURA Investigators. (2020). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382(1), 41-50. https://doi.org/10.1056/NEJMoa1913662

Raman, V., Jawitz, O. K., Yang, C. J., Tong, B. C., D'Amico, T. A., Berry, M. F., & Harpole, D. H. (2019a). Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. Annals of Thoracic Surgery, 108(2), 377-383. https://doi.org/10.1016/j.athoracsur.2019.03.053

Raman, V., Jawitz, O. K., Yang, C. J., Voigt, S. L., Tong, B. C., D'Amico, T. A., & Harpole, D. H. (2019b). Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. Journal of Thoracic Oncology, 14(12), 2143-2151. https://doi.org/10.1016/j.jtho.2019.09.005

Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J. Y., Orlov, S., Krzakowski, M., . . . LUME-Lung 1 Study Group. (2014a). Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncology, 15(2), 143-155. https://doi.org/10.1016/S1470-2045(13)70586-2

Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., . . . IMpower150 Study Group. (2019). Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respiratory medicine, 7(5), 387-401. https://doi.org/10.1016/S2213-2600(19)30084-0

Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K. M., Peters, S., & ESMO Guidelines Working Group. (2014b). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25 Suppl 3, iii27-39. https://doi.org/10.1093/annonc/mdu199

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., . . . KEYNOTE-024 Investigators. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375(19), 1823-1833. https://doi.org/10.1056/NEJMoa1606774

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., . . . BO17704 Study Group. (2010). Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology, 21(9), 1804-1809. https://doi.org/10.1093/annonc/mdq020

Refai, M., Brunelli, A., Salati, M., Pompili, C., Xiumè, F., & Sabbatini, A. (2011). Efficacy of anterior fissureless technique for right upper lobectomies: a case-matched analysis. European Journal of Cardio-Thoracic Surgery, 39(6), 1043-1046. https://doi.org/10.1016/j.ejcts.2010.09.039

Rekhtman, N. (2010). Neuroendocrine tumors of the lung: an update. Archives of Pathology and Laboratory Medicine, 134(11), 1628-1638. https://doi.org/10.5858/2009-0583-RAR.1

Rekhtman, N., Desmeules, P., Litvak, A. M., Pietanza, M. C., Santos-Zabala, M. L., Ni, A., . . . Lai, W. C. (2019). Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Modern Pathology, 32(8), 1106-1122. https://doi.org/10.1038/s41379-019-0248-2

Reveiz, L., Rueda, J. R., & Cardona, A. F. (2012). Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews, 12, CD004284. https://doi.org/10.1002/14651858.CD004284.pub3

Rheinheimer, S., Heussel, C. P., Mayer, P., Gaissmaier, L., Bozorgmehr, F., Winter, H., . . . Christopoulos, P. (2020). Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers, 12(4). https://doi.org/10.3390/cancers12041046

Ricciuti, B., Dahlberg, S. E., Adeni, A., Sholl, L. M., Nishino, M., & Awad, M. M. (2019). Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Journal of Clinical Oncology, JCO1900189. https://doi.org/10.1200/JCO.19.00189

Rieber, J., Schmitt, J., Warth, A., Muley, T., Kappes, J., Eichhorn, F., . . . Rieken, S. (2015). Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. European Journal of Medical Research, 20, 64. https://doi.org/10.1186/s40001-015-0158-9

Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., . . . OAK Study Group. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389(10066), 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X

Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., . . . Hodi, F. S. (2018). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 36(17), 1668-1674. https://doi.org/10.1200/JCO.2017.75.6270

Romi, F. (2011). Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Diseases, 2011, 474512. https://doi.org/10.4061/2011/474512

Romi, F., Skeie, G. O., Aarli, J. A., & Gilhus, N. E. (2000). Muscle autoantibodies in subgroups of myasthenia gravis patients. Journal of Neurology, 247(5), 369-375.

Ropper, A. E., & Ropper, A. H. (2017). Acute Spinal Cord Compression. New England Journal of Medicine, 376(14), 1358-1369. https://doi.org/10.1056/NEJMra1516539

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., . . . Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 13(3), 239-246. https://doi.org/10.1016/S1470-2045(11)70393-X

Rossi, G., Cavazza, A., Marchioni, A., Longo, L., Migaldi, M., Sartori, G., . . . Brambilla, E. (2005). Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. Journal of Clinical Oncology, 23(34), 8774-8785. https://doi.org/10.1200/JCO.2005.02.8233

Rostad, H., Naalsund, A., Jacobsen, R., Strand, T. E., Scott, H., Heyerdahl Strøm, E., & Norstein, J. (2004). Small cell lung cancer in Norway. Should more patients have been offered surgical therapy? European Journal of Cardio-Thoracic Surgery, 26(4), 782-786. https://doi.org/10.1016/j.ejcts.2004.06.011

Roth, K., Hardie, J. A., Andreassen, A. H., Leh, F., & Eagan, T. M. (2008). Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. BMC Pulmonary Medicine, 8, 2. https://doi.org/10.1186/1471-2466-8-2

Roth, K., Hardie, J. A., Andreassen, A. H., Leh, F., & Eagan, T. M. (2009). Cost minimization analysis for combinations of sampling techniques in bronchoscopy of endobronchial lesions. Respiratory Medicine, 103(6), 888-894. https://doi.org/10.1016/j.rmed.2008.12.012

Rowell, N. P., & Gleeson, F. V. (2001). Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database of Systematic Reviews, (4), CD001316.

Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., . . . Infectious Diseases Society of America. (2014). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clinical Infectious Diseases, 58(3), e44-100. https://doi.org/10.1093/cid/cit684

Rubins, J., Unger, M., Colice, G. L., & American College of Chest Physicians. (2007). Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest, 132(3 Suppl), 355S-367S. https://doi.org/10.1378/chest.07-1390

Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., . . . KEYNOTE-604 Investigators. (2020). Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology, 38(21), 2369-2379. https://doi.org/10.1200/JCO.20.00793

Rudin, C. M., Ismaila, N., Hann, C. L., Malhotra, N., Movsas, B., Norris, K., . . . Giaccone, G. (2015). Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. Journal of Clinical Oncology, 33(34), 4106-4111. https://doi.org/10.1200/JCO.2015.63.7918

Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., . . . Gazdar, A. F. (2019). Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews: Cancer, 19(5), 289-297. https://doi.org/10.1038/s41568-019-0133-9

Ruffini, E., Detterbeck, F., Van Raemdonck, D., Rocco, G., Thomas, P., Weder, W., . . . Venuta, F. (2014). Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database. Journal of Thoracic Oncology, 9, 541–548.

Rusch, V. W. (2006). Management of Pancoast tumours. Lancet Oncology, 7(12), 997-1005.

Rusch, V. W., Chansky, K., Kindler, H. L., Nowak, A. K., Pass, H. I., Rice, D. C., . . . IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions. (2016). The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology, 11(12), 2112-2119. https://doi.org/10.1016/j.jtho.2016.09.124

Rusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Winton, T., . . . Gandara, D. (2007). Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). Journal of Clinical Oncology, 25(3), 313-318.

Rusthoven, C. G., Yamamoto, M., Bernhardt, D., Smith, D. E., Gao, D., Serizawa, T., . . . Robin, T. P. (2020). Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA oncology, 6(7), 1028-1037. https://doi.org/10.1001/jamaoncol.2020.1271

Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., . . . Drilon, A. (2018). PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Annals of Oncology, 29(10), 2085-2091. https://doi.org/10.1093/annonc/mdy334

Sadikov, E., Bezjak, A., Yi, Q. L., Wells, W., Dawson, L., Millar, B. A., & Laperriere, N. (2007). Value of whole brain re-irradiation for brain metastases--single centre experience. Clinical Oncology (Royal College of Radiologists), 19(7), 532-538. https://doi.org/10.1016/j.clon.2007.06.001

Sagerup, C. M., Småstuen, M., Johannesen, T. B., Helland, Å., & Brustugun, O. T. (2011). Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax, 66(4), 301-307. https://doi.org/thx.2010.151621 [pii]


Saghir, Z., Dirksen, A., Ashraf, H., Bach, K. S., Brodersen, J., Clementsen, P. F., . . . Pedersen, J. H. (2012). CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax, 67(4), 296-301. https://doi.org/10.1136/thoraxjnl-2011-200736

Saji, H., Tsuboi, M., Matsubayashi, J., Miyajima, K., Shimada, Y., Imai, K., . . . Ikeda, N. (2010). Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anti-Cancer Drugs, 21(1), 89-93. https://doi.org/10.1097/CAD.0b013e328330fd79

Salati, M., & Brunelli, A. (2012). Preoperative assessment of patients for lung cancer surgery. Current Opinion in Pulmonary Medicine, 18(4), 289-294. https://doi.org/10.1097/MCP.0b013e3283539776

Salati, M., & Brunelli, A. (2016). Risk Stratification in Lung Resection. Current surgery reports, 4(11), 37. https://doi.org/10.1007/s40137-016-0158-x

Salazar, M. C., Rosen, J. E., Wang, Z., Arnold, B. N., Thomas, D. C., Herbst, R. S., . . . Boffa, D. J. (2017). Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA oncology, 3(5), 610-619. https://doi.org/10.1001/jamaoncol.2016.5829

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., . . . Johnson, D. H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 355(24), 2542-2550.

Santoro, A., O'Brien, M. E., Stahel, R. A., Nackaerts, K., Baas, P., Karthaus, M., . . . Manegold, C. (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. Journal of Thoracic Oncology, 3(7), 756-763. https://doi.org/10.1097/JTO.0b013e31817c73d6

Saunders, Y., Ross, J. R., Broadley, K. E., Edmonds, P. M., & Patel, S. (2004). Systematic review of bisphosphonates for hypercalcaemia of malignancy. Palliative Medicine, 18(5), 418-431. https://doi.org/10.1191/0269216304pm914ra

Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., . . . European Respiratory Society/European Society of Thoracic Surgeons Task Force. (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal, 35(3), 479-495. https://doi.org/10.1183/09031936.00063109

Schild, S. E., Bonner, J. A., Shanahan, T. G., Brooks, B. J., Marks, R. S., Geyer, S. M., . . . Jett, J. R. (2004). Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics, 59(4), 943-951.

Schild, S. E., Sio, T. T., Daniels, T. B., Chun, S. G., & Rades, D. (2017). Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. Journal of Oncology Practice, 13(11), 732-738. https://doi.org/10.1200/JOP.2017.026765

Schindewolf, M., & Weitz, J. I. (2020). Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thrombosis and Haemostasis, 120(1), 14-26. https://doi.org/10.1055/s-0039-3400302

Schmidt-Hansen, M., Baldwin, D. R., & Hasler, E. (2012). What is the most effective follow-up model for lung cancer patients? A systematic review. Journal of Thoracic Oncology, 7(5), 821-824. https://doi.org/10.1097/JTO.0b013e31824afc55

Schneider, B. J., Ismaila, N., Aerts, J., Chiles, C., Daly, M. E., Detterbeck, F. C., . . . Altorki, N. (2020). Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Journal of Clinical Oncology, 38(7), 753-766. https://doi.org/10.1200/JCO.19.02748

Schneider, B. J., Saxena, A., & Downey, R. J. (2011). Surgery for early-stage small cell lung cancer. Journal of the National Comprehensive Cancer Network, 9(10), 1132-1139.

Schneider, J. (2006). Tumor markers in detection of lung cancer. Advances in Clinical Chemistry, 42, 1-41.

Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., . . . Hellmann, M. D. (2019). Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of Oncology, 30(5), 839-844. https://doi.org/10.1093/annonc/mdz077

Schoenmaekers, J. J. A. O., Dingemans, A. C., & Hendriks, L. E. L. (2018). Brain imaging in early stage non-small cell lung cancer: still a controversial topic? Journal of Thoracic Disease, 10(Suppl 18), S2168-S2171. https://doi.org/10.21037/jtd.2018.06.68

Schoser, B., Eymard, B., Datt, J., & Mantegazza, R. (2017). Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. Journal of Neurology, 264(9), 1854-1863. https://doi.org/10.1007/s00415-017-8541-9

Schreiber, D., Rineer, J., Weedon, J., Vongtama, D., Wortham, A., Kim, A., . . . Rotman, M. (2010). Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer, 116(5), 1350-1357. https://doi.org/10.1002/cncr.24853

Schultheiss, T. E. (2008). The radiation dose-response of the human spinal cord. International Journal of Radiation Oncology, Biology, Physics, 71(5), 1455-1459. https://doi.org/10.1016/j.ijrobp.2007.11.075

Sculier, J. P., Berghmans, T., Castaigne, C., Luce, S., Sotiriou, C., Vermylen, P., & Paesmans, M. (1998). Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer, 19(2), 141-151.

Sechi, E., & Zekeridou, A. (2021). Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. Journal of Thoracic Oncology, 16(3), 381-394. https://doi.org/10.1016/j.jtho.2020.11.005

Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., . . . Schuler, M. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology, 31(27), 3327-3334. https://doi.org/10.1200/JCO.2012.44.2806

Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., . . . Rietschel, P. (2021). Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, 397(10274), 592-604. https://doi.org/10.1016/S0140-6736(21)00228-2

Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., . . . CROWN Trial Investigators. (2020). First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine, 383(21), 2018-2029. https://doi.org/10.1056/NEJMoa2027187

Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., . . . study investigators. (2016). Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncology, 17(2), 234-242. https://doi.org/10.1016/S1470-2045(15)00488-X

Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., . . . Iafrate, A. J. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. New England Journal of Medicine, 371(21), 1963-1971. https://doi.org/10.1056/NEJMoa1406766

Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C. C., Soo, R. A., . . . Martini, J. F. (2019a). Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 37(16), 1370-1379. https://doi.org/10.1200/JCO.18.02236

Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., . . . Ou, S. I. (2019b). Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncology. https://doi.org/10.1016/S1470-2045(19)30655-2

Shaw, P., & Agarwal, R. (2004). Pleurodesis for malignant pleural effusions. Cochrane Database of Systematic Reviews, (1).

Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., . . . Berille, J. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology, 18(10), 2095-2103.

Shirvani, S. M., Komaki, R., Heymach, J. V., Fossella, F. V., & Chang, J. Y. (2012). Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics, 82(1), e91-97. https://doi.org/10.1016/j.ijrobp.2010.12.072

Silvestri, G. A., Gould, M. K., Margolis, M. L., Tanoue, L. T., McCrory, D., Toloza, E., . . . American College of Chest Physicians. (2007). Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 178S-201S. https://doi.org/10.1378/chest.07-1360

Simon, G. R., Turrisi, A., & American College of Chest Physicians. (2007). Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 324S-339S. https://doi.org/10.1378/chest.07-1385

Simone, C. B. (2017). Thoracic Radiation Normal Tissue Injury. Seminars in Radiation Oncology, 27(4), 370-377. https://doi.org/10.1016/j.semradonc.2017.04.009

Singh, D., Chen, Y., Cummings, M. A., & Milano, M. T. (2019). Inoperable Pulmonary Carcinoid Tumors: Local Control Rates With Stereotactic Body Radiotherapy/Hypofractionated RT With Image-Guided Radiotherapy. Clinical Lung Cancer, 20(3), e284-e290. https://doi.org/10.1016/j.cllc.2019.02.003

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., . . . Govindan, R. (2021). Sotorasib for Lung Cancers with KRAS p.G12C Mutations. New England Journal of Medicine, 384(25), 2371-2381. https://doi.org/10.1056/NEJMoa2103695

Skov, B. G., & Skov, T. (2017). Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Applied Immunohistochemistry & Molecular Morphology, 25(7), 453-459. https://doi.org/10.1097/PAI.0000000000000540

Skulberg, A. K., Mathisen, L. C., & Vaagbø, G. (2016). Behandling av gassembolier. Tidsskrift for den Norske Legeforening, 136(12-13), 1070. https://doi.org/10.4045/tidsskr.16.0455

Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., . . . Senan, S. (2015). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet, 385(9962), 36-42. https://doi.org/10.1016/S0140-6736(14)61085-0

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., . . . IMpower150 Study Group. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 378(24), 2288-2301. https://doi.org/10.1056/NEJMoa1716948

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., . . . Shaw, A. T. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, 19(12), 1654-1667. https://doi.org/10.1016/S1470-2045(18)30649-1

Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., . . . PROFILE 1014 Investigators. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New England Journal of Medicine, 371(23), 2167-2177. https://doi.org/10.1056/NEJMoa1408440

Song, W. A., Zhou, N. K., Wang, W., Chu, X. Y., Liang, C. Y., Tian, X. D., . . . Dai, W. M. (2010). Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. Journal of Thoracic Oncology, 5(4), 510-516. https://doi.org/10.1097/JTO.0b013e3181cd3345

Sonobe, M., Yamada, T., Sato, M., Menju, T., Aoyama, A., Sato, T., . . . Date, H. (2014). Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Annals of Surgical Oncology, 21(8), 2546-2554. https://doi.org/10.1245/s10434-014-3630-9

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., . . . FLAURA Investigators. (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378, 113-125. https://doi.org/10.1056/NEJMoa1713137

Soria, J. C., Tan, D. S., Chiari, R., Wu, Y. L., Paz-Ares, L., Wolf, J., . . . de Castro, G. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, 389(10072), 917-929. https://doi.org/10.1016/S0140-6736(17)30123-X

Soria, J. C., Wu, Y. L., Nakagawa, K., Kim, S. W., Yang, J. J., Ahn, M. J., . . . Mok, T. S. (2015). Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology, 16(8), 990-998. https://doi.org/10.1016/S1470-2045(15)00121-7

Spigel, D., McLeod, M., Hussein, M., Waterhouse, D., Einhorn, L., Horn, L., . . . Jotte, R. (2017). Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology, 28, v460-v496.

Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., . . . Reck, M. (2021). Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Annals of Oncology, 32(5), 631-641. https://doi.org/10.1016/j.annonc.2021.01.071

Spiro, S. G. (2012). Screening for lung cancer: we still need to know more. Thorax, 67(4), 283-285. https://doi.org/10.1136/thoraxjnl-2011-201541

Stahel, R. A., Weder, W., Lievens, Y., Felip, E., & ESMO Guidelines Working Group. (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21 Suppl 5, v126-128. https://doi.org/10.1093/annonc/mdq173

Stanic, S., Paulus, R., Timmerman, R. D., Michalski, J. M., Barriger, R. B., Bezjak, A., . . . Bradley, J. (2014). No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. International Journal of Radiation Oncology, Biology, Physics, 88(5), 1092-1099. https://doi.org/10.1016/j.ijrobp.2013.12.050

Stovold, R., Blackhall, F., Meredith, S., Hou, J., Dive, C., & White, A. (2012). Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer, 76(3), 263-268. https://doi.org/10.1016/j.lungcan.2011.11.015

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., . . . NETTER-1 Trial Investigators. (2017). Phase 3 Trial of. New England Journal of Medicine, 376(2), 125-135. https://doi.org/10.1056/NEJMoa1607427

Strøm, H. H., Bremnes, R. M., Sundstrøm, S. H., Helbekkmo, N., Fløtten, O., & Aasebø, U. (2013). Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer, 109(6), 1467-1475. https://doi.org/10.1038/bjc.2013.466

Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., . . . Mentzer, S. J. (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. Journal of Thoracic and Cardiovascular Surgery, 117(1), 54-63.

Suh, J. H. (2010). Stereotactic radiosurgery for the management of brain metastases. New England Journal of Medicine, 362(12), 1119-1127. https://doi.org/10.1056/NEJMct0806951

Sun, J. M., Ahn, M. J., Ahn, J. S., Um, S. W., Kim, H., Kim, H. K., . . . Park, K. (2012). Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer, 77(2), 365-370. https://doi.org/10.1016/j.lungcan.2012.04.009

Sun, L., Davis, C. W., Hwang, W. T., Jeffries, S., Sulyok, L. F., Marmarelis, M. E., . . . Aggarwal, C. (2020). Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2020.10.017

Sundstrom, S., Bremnes, R., Brunsvig, P., Aasebo, U., Olbjorn, K., Fayers, P. M., & Kaasa, S. (2005). Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiotherapy and Oncology, 75(2), 141-148.

Sundstrom, S., Bremnes, R., Aasebo, U., Aamdal, S., Hatlevoll, R., Brunsvig, P., . . . Kaasa, S. (2004). Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. Journal of Clinical Oncology, 22(5), 801-810.

Sundstrom, S., Bremnes, R. M., Kaasa, S., Aasebo, U., Hatlevoll, R., Dahle, R., . . . Aamdal, S. (2002). Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. Journal of Clinical Oncology, 20(24), 4665-4672.

Sørensen, M., Pijls-Johannesma, M., Felip, E., & ESMO Guidelines Working Group. (2010). Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21 Suppl 5, v120-125. https://doi.org/10.1093/annonc/mdq172

Sørensen, S., Helweg-Larsen, S., Mouridsen, H., & Hansen, H. H. (1994). Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. European Journal of Cancer, 30A(1), 22-27.

Takamochi, K., Yoshida, J., Murakami, K., Niho, S., Ishii, G., Nishimura, M., . . . Nagai, K. (2005). Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer, 47(2), 235-242. https://doi.org/10.1016/j.lungcan.2004.08.004

Takenaka, D., Ohno, Y., Koyama, H., Nogami, M., Onishi, Y., Matsumoto, K., . . . Sugimura, K. (2010). Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. European Journal of Radiology, 74(3), 458-464. https://doi.org/10.1016/j.ejrad.2009.03.007

Tan, B. B., Flaherty, K. R., Kazerooni, E. A., Iannettoni, M. D., & American College of Chest Physicians. (2003). The solitary pulmonary nodule. Chest, 123(1 Suppl), 89S-96S.

Tassinari, D., Scarpi, E., Sartori, S., Tamburini, E., Santelmo, C., Tombesi, P., & Lazzari-Agli, L. (2009). Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest, 135(6), 1596-1609.

Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., . . . Lynch, T. J. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. New England Journal of Medicine, 363(8), 733-742. https://doi.org/10.1056/NEJMoa1000678

Teraoka, S., Fujimoto, D., Morimoto, T., Kawachi, H., Ito, M., Sato, Y., . . . Tomii, K. (2017). Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. Journal of Thoracic Oncology, 12(12), 1798-1805. https://doi.org/10.1016/j.jtho.2017.08.022

Thatcher, N., Nicolson, M., Groves, R. W., Steele, J., Eaby, B., Dunlop, J., . . . Ukachukwu, I. (2009). Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. Oncologist, 14(8), 840-847.

Travis, W. D. (2014). Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thoracic Surgery Clinics, 24(3), 257-266. https://doi.org/10.1016/j.thorsurg.2014.04.001

Travis, W. D., Asamura, H., Bankier, A. A., Beasley, M. B., Detterbeck, F., Flieder, D. B., . . . International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and Advisory Board Members. (2016). The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 11(8), 1204-1223. https://doi.org/10.1016/j.jtho.2016.03.025

Travis, W. D., Brambilla, E., Rami-Porta, R., Vallières, E., Tsuboi, M., Rusch, V., . . . International Staging Committee. (2008). Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 3(12), 1384-1390. https://doi.org/10.1097/JTO.0b013e31818e0d9f

Treasure, T., Lang-Lazdunski, L., Waller, D., Bliss, J. M., Tan, C., Entwisle, J., . . . MARS trialists. (2011). Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncology, 12(8), 763-772. https://doi.org/10.1016/S1470-2045(11)70149-8

Truong, M. T., Ko, J. P., Rossi, S. E., Rossi, I., Viswanathan, C., Bruzzi, J. F., . . . Erasmus, J. J. (2014). Update in the evaluation of the solitary pulmonary nodule. Radiographics, 34(6), 1658-1679. https://doi.org/10.1148/rg.346130092

Tsuruoka, K., Horinouchi, H., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., . . . Ohe, Y. (2017). PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 108, 115-120. https://doi.org/10.1016/j.lungcan.2017.03.006

Tsuya, A., Kurata, T., Tamura, K., & Fukuoka, M. (2007). Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer, 57(2), 229-232.

Turner, M. C., Andersen, Z. J., Baccarelli, A., Diver, W. R., Gapstur, S. M., Pope, C. A., . . . Cohen, A. (2020). Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21632

Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., . . . Johnson, D. H. (1999). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New England Journal of Medicine, 340(4), 265-271.

Vallieres, E., Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., . . . Goldstraw, P. (2009). The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 4(9), 1049-1059.

van Loon, J., De Ruysscher, D., Wanders, R., Boersma, L., Simons, J., Oellers, M., . . . Lambin, P. (2010). Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. International Journal of Radiation Oncology, Biology, Physics, 77(2), 329-336. https://doi.org/10.1016/j.ijrobp.2009.04.075

van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., . . . Giaccone, G. (2005). Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. Journal of Clinical Oncology, 23(28), 6881-6889.

van Meerbeeck, J. P., Kramer, G. W., Van Schil, P. E., Legrand, C., Smit, E. F., Schramel, F., . . . European Organisation for Research and Treatment of Cancer-Lung Cancer Group. (2007). Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. Journal of the National Cancer Institute, 99(6), 442-450. https://doi.org/10.1093/jnci/djk093

van Thiel, E. R., Surmont, V. F., & van Meerbeeck, J. P. (2011). Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Review of Anticancer Therapy, 11(4), 551-560. https://doi.org/10.1586/era.10.169

Vellayappan, B., Tan, C. L., Yong, C., Khor, L. K., Koh, W. Y., Yeo, T. T., . . . Sahgal, A. (2018). Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases. Frontiers in Oncology, 8, 395. https://doi.org/10.3389/fonc.2018.00395

Vergnon, J. M., Huber, R. M., & Moghissi, K. (2006). Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. European Respiratory Journal, 28(1), 200-218.

Veronesi, G., Morandi, U., Alloisio, M., Terzi, A., Cardillo, G., Filosso, P., . . . Spaggiari, L. (2006). Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer, 53(1), 111-115. https://doi.org/10.1016/j.lungcan.2006.03.007

Veronesi, G., Novellis, P., Voulaz, E., & Alloisio, M. (2016). Robot-assisted surgery for lung cancer: State of the art and perspectives. Lung Cancer, 101, 28-34. https://doi.org/10.1016/j.lungcan.2016.09.004

Vilmann, P., Clementsen, P. F., Colella, S., Siemsen, M., De Leyn, P., Dumonceau, J. M., . . . Annema, J. T. (2015). Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy, 47(6), c1. https://doi.org/10.1055/s-0034-1392453

Vogelius, I. R., & Bentzen, S. M. (2012). A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncologica, 51(8), 975-983. https://doi.org/10.3109/0284186X.2012.718093

Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., . . . Paoletti, P. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21(14), 2636-2644.

von Meyenfeldt, E. M., Prevoo, W., Peyrot, D., Lai A Fat, N., Burgers, S. J., Wouters, M. W., & Klomp, H. M. (2011). Local progression after radiofrequency ablation for pulmonary metastases. Cancer, 117(16), 3781-3787. https://doi.org/10.1002/cncr.25958

von Pawel, J., Gatzemeier, U., Pujol, J. L., Moreau, L., Bildat, S., Ranson, M., . . . Ross, G. (2001). Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. Journal of Clinical Oncology, 19(6), 1743-1749.

von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., . . . Gralla, R. (1999). Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of Clinical Oncology, 17(2), 658-667.

von Plessen, C., Bergman, B., Andresen, O., Bremnes, R. M., Sundstrom, S., Gilleryd, M., . . . Sorenson, S. (2006). Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. British Journal of Cancer, 95(8), 966-973. https://doi.org/6603383 [pii] 10.1038/sj.bjc.6603383

Wahidi, M. M., Govert, J. A., Goudar, R. K., Gould, M. K., McCrory, D. C., & American College of Chest Physicians. (2007). Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 94S-107S. https://doi.org/10.1378/chest.07-1352

Wahl, S. G. F., Dai, H. Y., Emdal, E. F., Berg, T., Halvorsen, T. O., Ottestad, A. L., . . . Richardsen, E. (2021). The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study. Cancers, 13(17). https://doi.org/10.3390/cancers13174294

Waite, K., & Gilligan, D. (2007). The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clinical Oncology (Royal College of Radiologists), 19(3), 182-187. https://doi.org/S0936-6555(06)00435-3 [pii] 10.1016/j.clon.2006.12.006

Waldeland, E., Brustugun, O. T., Ramberg, C., & Helland, Å. (2012). Stereotaktisk bestråling av columnametastaser. Tidsskrift for den Norske Legeforening, 132(22), 2478-2479. https://doi.org/10.4045/tidsskr.12.1108

Walji, N., Chan, A. K., & Peake, D. R. (2008). Common acute oncological emergencies: diagnosis, investigation and management. Postgraduate Medical Journal, 84(994), 418-427.

Wang, E. H., Corso, C. D., Rutter, C. E., Park, H. S., Chen, A. B., Kim, A. W., . . . Yu, J. B. (2015). Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 33(25), 2727-2734. https://doi.org/10.1200/JCO.2015.61.1517

Warren, G. W., Alberg, A. J., Kraft, A. S., & Cummings, K. M. (2014). The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer, 120(13), 1914-1916. https://doi.org/10.1002/cncr.28695

Watanabe, S. M., Nekolaichuk, C. L., & Beaumont, C. (2012). The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement. Psycho-Oncology, 21(9), 977-985. https://doi.org/10.1002/pon.1996

Weder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., . . . Swiss Group for Clinical Cancer Research. (2007). Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Annals of Oncology, 18(7), 1196-1202. https://doi.org/10.1093/annonc/mdm093

Wei, M. L., Kang, D., Gu, L., Qiu, M., Zhengyin, L., & Mu, Y. (2013). Chemotherapy for thymic carcinoma and advanced thymoma in adults. Cochrane Database of Systematic Reviews, 8, CD008588. https://doi.org/10.1002/14651858.CD008588.pub2

Weichselbaum, R. R., & Hellman, S. (2011). Oligometastases revisited. Nature Reviews: Clinical Oncology, 8(6), 378-382. https://doi.org/10.1038/nrclinonc.2011.44

Westphalen, C. B., Krebs, M. G., Le Tourneau, C., Sokol, E. S., Maund, S. L., Wilson, T. R., . . . de Braud, F. (2021). Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ precision oncology, 5(1), 69. https://doi.org/10.1038/s41698-021-00206-y

WHO Classification of Tumours Editorial Board (red.). (2021). Thoracic tumours (5. utg.). (WHO Classification of Tumours Volume 5). Lyon: International Agency for Research on Cancer.

Wijn, D. H., Groeneveld, G. H., Vollaard, A. M., Muller, M., Wallinga, J., Gelderblom, H., & Smit, E. F. (2018). Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. European Journal of Cancer, 104, 182-187. https://doi.org/10.1016/j.ejca.2018.09.012

Wilson, J. M., & Jungner, Y. G. (1968). [Principles and practice of mass screening for disease]. Boletín de la Oficina Sanitaria Panamericana, 65(4), 281-393.

Wilson, L. D., Detterbeck, F. C., & Yahalom, J. (2007). Clinical practice. Superior vena cava syndrome with malignant causes. New England Journal of Medicine, 356(18), 1862-1869.

Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., . . . Shepherd, F. (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. New England Journal of Medicine, 352(25), 2589-2597.

Wirth, L. J., Carter, M. R., Jänne, P. A., & Johnson, B. E. (2004). Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer, 44(2), 213-220. https://doi.org/10.1016/j.lungcan.2003.11.016

Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J. M., . . . GEOMETRY mono-1 Investigators. (2020). Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. New England Journal of Medicine, 383(10), 944-957. https://doi.org/10.1056/NEJMoa2002787

Wolfson, A. H., Bae, K., Komaki, R., Meyers, C., Movsas, B., Le Pechoux, C., . . . Choy, H. (2011). Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics, 81(1), 77-84. https://doi.org/10.1016/j.ijrobp.2010.05.013

Wolin, E. M. (2017). Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung. Chest, 151(5), 1141-1146. https://doi.org/10.1016/j.chest.2016.06.018

Wu, Y. L., Ahn, M. J., Garassino, M. C., Han, J. Y., Katakami, N., Kim, H. R., . . . Mok, T. S. K. (2018). CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). Journal of Clinical Oncology, 36(26), 2702-2709. https://doi.org/10.1200/JCO.2018.77.9363

Wu, Y. L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., . . . Mok, T. S. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncology, 18(11), 1454-1466. https://doi.org/10.1016/S1470-2045(17)30608-3

Wu, Y. L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., . . . ADAURA Investigators. (2020). Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. New England Journal of Medicine, 383(18), 1711-1723. https://doi.org/10.1056/NEJMoa2027071

Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., . . . Jokura, H. (2014). Stereotactic radiosurgery for patients with brain metastases - authors' reply. Lancet Oncology, 15(7), e248. https://doi.org/10.1016/S1470-2045(14)70221-9

Yang, J. C., Schuler, M., Popat, S., Miura, S., Heeke, S., Park, K., . . . Kim, E. S. (2020). Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of Thoracic Oncology, 15(5), 803-815. https://doi.org/10.1016/j.jtho.2019.12.126

Yang, J. C., Sequist, L. V., Geater, S. L., Tsai, C. M., Mok, T. S., Schuler, M., . . . Wu, Y. L. (2015). Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology, 16(7), 830-838. https://doi.org/10.1016/S1470-2045(15)00026-1

Yang, S. Y., Kim, D. G., Lee, S. H., Chung, H. T., Paek, S. H., Hyun Kim, J., . . . Han, D. H. (2008). Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer, 112(8), 1780-1786. https://doi.org/10.1002/cncr.23357

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., . . . RAD001 in Advanced Neuroendocrine Tumours, F. u. T. R.-S. G. (2016). Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, 387(10022), 968-977. https://doi.org/10.1016/S0140-6736(15)00817-X

Yokoba, M., Ichikawa, T., Harada, S., Naito, M., Sato, Y., & Katagiri, M. (2018). Postoperative pulmonary function changes according to the resected lobe: a 1-year follow-up study of lobectomized patients. Journal of Thoracic Disease, 10(12), 6891-6902. https://doi.org/10.21037/jtd.2018.11.108

Yu, J. B., Decker, R. H., Detterbeck, F. C., & Wilson, L. D. (2010). Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. Journal of Thoracic Oncology, 5(2), 215-219. https://doi.org/10.1097/JTO.0b013e3181cd3208

Yuen, A. R., Zou, G., Turrisi, A. T., Sause, W., Komaki, R., Wagner, H., . . . Johnson, D. H. (2000). Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer, 89(9), 1953-1960.

Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., . . . French Cooperative Thoracic Intergroup (IFCT). (2016). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 387(10026), 1405-1414. https://doi.org/10.1016/S0140-6736(15)01238-6

Zeng, H., De Ruysscher, D., X, H., Zheng, D., Yang, L., Ricardi, U., . . . Hendriks, L. (2022). Radiotherapy for small cell lung cancer in current clinical practice guidelines. Journal of the National Cancer Center, 2(2), 113-125.

Zhao, C., & Rajan, A. (2019). Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? Mediastinum, 3. https://doi.org/10.21037/med.2019.08.02

Zhu, H., Guo, H., Shi, F., Zhu, K., Luo, J., Liu, X., . . . Yu, J. (2014). Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage I disease. Lung Cancer, 86(3), 334-338. https://doi.org/10.1016/j.lungcan.2014.09.019

Zhu, Z., Ni, J., Cai, X., Su, S., Zhuang, H., Yang, Z., . . . Fu, X. (2022). International consensus on radiotherapy in metastatic non-small cell lung cancer. Translational lung cancer research, 11(9), 1763-1795. https://doi.org/10.21037/tlcr-22-644

Sist faglig oppdatert: 06. januar 2023